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Zusammenfassung
Das multiple Myelom (MM) ist eine maligne Erkrankung, die durch die Entar-
tung reifer Plasmazellen im Knochenmark charakterisiert ist. Im Krankheitsver-
lauf kommt es zu einer verstärkten Proliferation und Expansion von MM Zellen
im Knochenmark. In einigen Fällen tritt eine übermäßige Produktion von Pro-
teinen (Immunglobulinen), die im Blut oder Urin nachgewiesen werden können,
auf. Bei vielen Patienten kommt es zudem zu einem Abbau des Knochengewebes
durch eine vermehrte Aktivierung von Osteoclasten (Knochen-abbauende Zellen).
Ohne Therapie überleben Betroffene ca. 3-6 Monate, mit den momentan gegebe-
nen Therapiemöglichkeiten erhöht sich die Überlebenserwartung auf ca. 3-6 Jahre.
Die Krankheitsentwicklung wird imWesentlichen vomMikromilieu im Knochenmark
bestimmt, da die MM-Zellen gezielt ins Knochenmark einwandern können (Homing)
und dort angiogene Prozesse auslösen, was zur Vaskularisierung des Tumorgewebes
führt.
Die vorliegende Arbeit beschäftigt sich mit dem Einfluss von Galektin-8 (Gal-8),
einem zuckerbindenden Protein (Lektin), welches zwei Kohlenhydrat-Binderegionen
besitzt die durch eine Peptid Linker-Region miteinander verbunden sind, auf den
Verlauf des MM. Ich konnte nachweisen, das Gal-8 im Serum vom MM Patienten im
Vergleich zu gesunden Probanden erhöht ist und das eine hohe Gal-8 Expression auf
mRNA Ebene mit einer schlechteren Überlebensprognose korreliert. Durch in vitro
Experimente konnte ich zeigen, dass Gal-8 sowohl an MM als auch an Endothelzellen
bindet und keinen Effekt auf die Angiogenese hat, dafür jedoch auf das Homing von
MM Zellen an das Gefäßendothel. Die erhöhte Bindung durch die Gabe von rekom-
binantem Gal-8 von MM Zellen an Endothelzellen konnte sowohl statisch, als auch
dynamisch während einer Simulation des Blutflusses, nachgewiesen werden. Auch
durch Zugabe von Gal-8 aus konditionierten MM Überständen ist eine Erhöhung der
Adhäsion nachweisbar. Es gibt zwei verschiedene Isoformen des Proteins, die sich in
der Länge des Polypeptid-Linkers unterscheiden (S-kurz; L-lang), der pro-adhäsive
Effekt tritt vor allem bei Zugabe der Gal-8L Isoform auf. Dass vor allem die Isoform
mit dem langen Peptid-Linker die Adhäsion stark erhöht, lässt sich eventuell mit der
Bildung von Gal-8 Komplexen erklären. Obwohl seit langem von solchen extrazel-
lulären Galektin-Komplexen hypothetisch ausgegangen wird, konnten diese bisher
noch nicht eindeutig nachgewiesen werden. Ich konnte mit Hilfe der Thermophorese
zeigen, dass Gal-8L in der Lage ist in einen multimeren Zustand überzugehen. In-
teressanterweise geschieht dies ohne die Interaktion mit einem Zuckerliganden. Die
Tatsache, dass sich Gal-8S und Gal-8L in Lösung unterschiedlich verhalten, kann
wiederum Auswirkungen auf die unterschiedliche biologische Aktivität der zwei Iso-
formen haben.
Summary
Multiple myeloma (MM) is a hematological malignancy characterized by the
clonal proliferation of mature plasma cells in the bone marrow. During the pro-
gression of the disease, post-germinal B-cells proliferate and expand rapidly. In some
cases, high amounts of proteins (immunoglobulins) can be detected in blood or urine.
Additionally, many patients suffer from an activation of osteoclasts (cells that resorb
bone). Without therapy, patients survive 3-6 months, treatment with state-of-the-
art therapy prolongs the life expectation to 3-6 years. The progression of the disease
depends on the microenvironment in the bone marrow, since MM cells migrate into
the bone marrow (homing) leading to increased tumorangiogenesis promoting the
vascularization of the tumor.
My thesis is about the influence of Galectin-8 (Gal-8) on the interaction of MM
with endothelial cells (EC). Gal-8 is a carbohydrate binding protein (lectin) that
consists of two carbohydrate recognition domains (CRD) connected by a peptide
linker. I was able to show that the content of the Gal-8 protein in the serum of MM
patients is higher compared to healthy donors and that high expression of Gal-8 on
mRNA level correlates with a poor prognosis. Using several in vitro approaches, I
showed that Gal-8 binds both, MM and EC and has no effect on angiogenesis, but
on homing of MM to EC. Recombinant Gal-8 enhances the binding of MM cells to
EC is in static, as well as in shear stress conditions during the simulation of blood
flow. Gal-8 conditioned MM supernatants were also capable of promoting adhesion.
Gal-8 appears in two isoforms differing in the length of the linker peptide (S-short;
L-long), the pro-adhesive effect is particularly stronger by the addition of the Gal-8L
isoform. This effect might be explained by the formation of Gal-8 complexes. Al-
though these processes have been assumed hypothetically, no experimental evidence
exists. Using thermophoresis, I was now able to show that Gal-8L can form mul-
timers. Interestingly, this happens without the addition of a carbohydrate ligand.
These findings are in contrast to the existing interaction-models. The measurements
show that Gal-8S and Gal-8L act differently in solution, this could have an impact
on the biological activity of both isoforms.
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1Introduction
1.1 Clinical aspects on Multiple Myeloma
Multiple myeloma (MM) is a hematologic malignancy characterized by the transfor-
mation and clonal proliferation of mature plasma cells in the bone marrow (BM) [1].
According to the “Surveillance, Epidemiology, and End Results Program” (SEER)
statistic in 2012, the median age at diagnosis is 69. In between 2003-2009, the 5 year
survival rate was 43.2%, the median age at death is 75 years. In 2013, the number
of estimated new cases was 22,350 which is 1.3% of all cancer cases in the USA [2].
MM evolves from a monoclonal gammopathy of undetermined significance (MGUS)
that progresses from asymtomatical myeloma (smoldering myeloma, SMM) to the
symptomatic MM [3]. Diagnostic criteria for the staging of the disease are summa-
rized in Table 1.1.
MGUS SMM MM
Serum M protein 3g per 100ml ≥3g per 10ml 3g per 100ml
Bone marrow
plasma cells
<10% ≥10% >10%
Urine light chain
protein
none none >1g per day
Table 1.1: Staging criteria of MM (according to Anderson et al. [3])
MGUS: monoclonal gammopathy of undetermined significance; SMM: smoldering myeloma; MM: multiple
myeloma.
The prevalence of MGUS is 3.2% in persons older than 50 years, 0.5%-3% of
people having MGUS progress to MM per year [3, 4]. Not much is known about
the process that drives the development from MGUS to MM. Active MM is defined
by the occurrence of CRAB criteria (HyperCalcemia (serum calcein >11.5mg/dl),
Renal insufficiency (serum creatinine >2mg/dl), Anemia (hemoglobin >10g/dl or
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>2g/dl below the lower limit of the normal range) and Bone disease such as lytic
lesions, osteopenia or pathologic fracture [1]. Patients present usually with unspecific
pain in their back and a general lethargy which makes MM difficult to diagnose [5].
In the course from MGUS to MM, several genetic aberrations occur leading to
the manifestation of the disease (Figure 1.1) [6]. MM cells are very heterogenous
caused by their origin from long-lived plasma cells, which are already highly diverse,
and many different genetic alterations appear during the progression of the disease
(chromosomal translocations or the loss or gain of chromosomes).
Figure 1.1: Oncogenic events during MM progression
In the progression from MGUS to MM, several genetic lesions occur. The figure was taken and modified
from Kuehl and Bergsagel [7].
Using the mSMART (Mayo Stratification of Myeloma and Risk-Adapted Ther-
apy) classification, patients are classified according to their genetic abnormalities in
high-, intermediate- and standard-risk (Table 1.2) [8].
High risk Intermediate risk Standard risk
del 17p t(4;14) t(11;14)
t(14;16) cytogenic del 13 t(6;14)
t(14;20) hypodiploidy all others
GEP: high risk
signature
PCLI≥3%
Table 1.2: Risk stratification
Frequent genetic alterations are used to classify patients according to the “Mayo Stratification of Myeloma
and Risk-Adapted Therapy” (mSMART) [8]. GEP=gene expression profiling; PCLI=plasma cell labeling
index
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Treatment is not curative at the moment, but can prolong the life expectation of pa-
tients. Currently, five different classes of therapeutics are available: alkylating agents
such as melphalan, anthracyclines like adriamycin and liposomal doxorubicin, corti-
costeroids (dexamethasone and prednisone), immunomodulatory drugs (thalidomide
and lenalidomide), and proteasome inhibitors, e.g. bortezomib and carfilzomib [8].
Additionally, there is the possibility of autologous stem cell transplantation, which
improves progression-free survival as well as over-all survival of patients [9]. Treat-
ment options have to be optimized for each patient after diagnosis and staging of
the disease.
1.2 Biology of MM in the BM
Understanding MM progression on a molecular level is crucial in order to find new
treatment options and to understand why MGUS develops to MM. During the pro-
gression of the disease, MM cells home into the BM and are able to modify stromal
cells in their host according to their requirements, promote the vascularization of
the neoplasm (tumor angiogenesis) and cause bone resorption (osteolysis) as a con-
sequence of activation of osteoclasts [10].
The BM microenvironment consists of several components like the extracellular
matrix (ECM), bone marrow stromal cells (BMSC), fibroblasts, osteoblasts, osteo-
clasts, adipocytes and endothelial cells (EC) [11]. ECM and bone marrow cells are
all in close contact and being altered by the invading MM cells. Since MM cells
depend on the BM microenvironment for their growth and viability, they induce
many signaling pathways to ensure their survival. This leads to a highly complex
and interactive signaling network within the BM (Figure 1.2).
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Figure 1.2: Interactions of MM cells with the BM microenvironment
Binding of the MM cells to BMSC triggers the transcription and expression of many factors, like IL-6,
VEGF, TNFa, IGF1, SDF-1a, IL-1beta and MIP-1a. Those are able to mediate MM cell survival and
proliferation in the BM [11, 12]. Many characteristics of the disease are due to those factors remodeling the
BM. MM cells are able to induce osteolytic bone lesions by stimulating osteoclasts. They produce RANK-
ligand (RANKL) which can bind to osteoclasts, leading to their activation and the downregulation of OPG
expression, which is an inhibitor of RANKL. Another example is the expression of macrophage inhibitory
protein alpha (MIP-1a) which is another activator of osteoclasts. After activation by MM cells, osteoclasts
themselves produce IL-6 and osteopontin. Those factors stimulate the growing and survival of MM cells
in the BM [7]. Another hallmark of MM progression is the induction of bone marrow angiogenesis. Either
the direct production of pro-angiogenic molecules by MM cells or their induction in stromal cells or EC
lead to the formation of tumor blood vessels in the BM. Adhesion molecules like VLA-4, VCAM or ICAM
induce the adhesion of MM cells to the BM microenvironment. (The figure was taken from Palumbo and
Anderson [1])
Complex interactions between MM cells and EC in the BM influence the processes
of MM development. They are on the one hand involved in tumor-angiogenesis
and on the other hand in the homing of the malignant cells into the BM. Further
investigations are necessary in order to obtain deeper insights into the complex
interplay between MM and EC in the context of the BM microenvironment.
1.2.1 Angiogenesis
Angiogenesis is a process leading to the formation of a new blood vessel network.
The vasculature is important for the supply of all organs with oxygen and nutri-
ents but also the disposal of cellular waste and immune cell trafficking into inflamed
tissues [13]. All mammalian cells must be located within 100-200µm of a blood ves-
sel in order to ensure their survival, since the diffusion limit of oxygen lies within
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that distance. Organs growing beyond this size need to induce the formation of a
blood vessel system to guarantee their survival [14]. After building a vessel net-
work during embryogenesis de novo, EC usually remain quiescent and are able to
survive for years. In healthy adults, active angiogenesis only occurs after injuries,
when wounds have to be repaired or in female reproductive organs during menstru-
ation [15, 16, 17]. Three distinct modes of vessel formation have been described so
far (Figure 1.3). Vasculogenesis is the differentiation of endothelial precursor cells
(angioblasts) into EC and their de novo assemble to a vasculature. This process
occurs during embryogenesis. Sprouting angiogenesis describes the expansion of a
preexisting network, intussuseption is the split of one vessel into two new vessels
[13, 18]. During these processes, complex and dynamic interactions between EC and
extracellular microenvironment occur [18].
A B C
Figure 1.3: New blood vessel formation
The formation of new blood vessels can occur by several distinct mechanisms. A: Sprouting angiogenesis
extends an already existing network B: Vasculogenesis occurs during embryogenesis to built the vasculature
de novo C: Splitting of a pre-existing vessel by intussuseption. (The figure was taken and modified from
Carmeliet and Jain [13])
Vessel formation is a tightly regulated process driven by several pro-and anti-
angiogenic factors [14]. Members of the vascular endothelial growth factor (VEGF)
family are the predominant signaling molecules for the induction of angiogenesis.
The family consists of only a few members, VEGF-A being the most important one
signaling by binding to VEGF receptor 2 (VEGF-R2) [13, 19]. Neuropilins (NRP1
and NRP2) are co-receptors that are on the one hand able to enhance VEGF-R2
activity or, on the other hand, signal independently [13, 20]. Many other factors are
also involved in angiogenesis, e.g. fibroblast growth factors (FGF), platelet-derived
growth factors (PDGF) angiopoietins (ANG) and several integrins and proteases[13,
19]. Since in adults EC are mostly quiescent and the vasculature remains stable, these
growth factors need to be tightly balanced [13].
As Hanahan and Weinberg described the six hallmarks of cancer in 2000, angio-
genesis was one among them, highlighting the importance of this process in tumor
biology [21, 22]. Like all other organs, tumors are dependent on the constant supply
with oxygen and nutrients [15]. If tumors grow beyond sizes of 100-200µm, a blood
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vessel system is needed to enable further cell growth and metastasizing (Figure 1.4)
[14]
angiogenic switch
tumor mass
Transformation
Dormant
tumor
vascularized
metastatic
tumor
undetectable
tumor
clinically
detectable
tumor
Figure 1.4: Angiogenic switch
Small, clinically undetectable tumors do not need blood vessels for growing. If the tumor mass reaches a
certain size (100-200µm), the cells need blood vessels for the supply with nutrients and oxygen and for
metastasizing. (The figure was taken and modified from Albini et al. [23])
Even though hematologic tumors, like MM, do not consist of a solid tumor mass,
they depend on the vasculature and promote tumor angiogenesis. A high micro vessel
density in the BM of MM patients has been observed already in studies from 1994
by Vacca et al. [24]. Several studies have shown that the occurrence of a higher micro
vessel density in MM is a marker for faster progression [25, 26]. Additionally, several
pro-angiogenic factors, like FGF-2 or VEGF are upregulated during the progression
of the disease leading to the vascularization of the tumor in the BM [25, 26, 27].
These findings lead to a hypothetical model by Vacca and Ribatti [26] (Figure 1.5).
They proposed that MGUS, the preliminary stage of MM, is the avascular phase not
depending on tumor angiogenesis. After certain transformation events (activation
of oncogenes, inactivation of tumor-suppressor genes) cells start to proliferate and
secrete chemokines and cytokines leading to the angiogenic switch. Fully established
MM is in a vascular phase where many proliferating clones are located in the BM
and in the blood stream [26, 27]. The mechanisms why MGUS progresses to MM
and how this angiogenic switch occurs are still unknown [26].
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Figure 1.5: Angiogenesis and the angiogenic switch in MM
Hypothesis on the progression of MM in the BM. During the early avascular phase, MM cells do not need
a tumor vasculature. Normal plasma cells transform due to certain genetic alterations to non-proliferating
malignant clones (MGUS). After massive proliferation and reaching a certain size, tumor cells start to
induce tumor angiogenesis by secreting pro-angiogenic molecules, e.g. VEGF. This leads to an establishment
of the disease. (The figure was taken from Vacca and Ribatti [26])
1.2.2 Homing
Besides angiogenesis, the invasion and homing of MM cells into the BM is a hallmark
of the disease. Although MM cells in the BM represent most of the tumor mass, a
small number of cells is able to circulate in the blood vessel system [28]. These cells
most likely represent the tumor-spreading component of the disease. These findings
show that MM cells have capacity to (re)circulate, extravasate and migrate back
into the BM showing how important homing mechanisms are for the progression
of the disease [10]. In later stages of the disease, MM cells are able to become BM
independent, meaning they are able to survive without BM stroma, leading to an
increased number of circulating cells in the blood stream [29, 30].
The leucocyte adhesion cascade was described in 1990 by Butcher and Picker [31]
and in extended form in 2007 by Ley et al. [32]. The adhesion of leucocytes to EC
can be separated into several distinct steps all needing to be highly specific in order
to only allow the immune cells to bind (Figure 1.6).
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Figure 1.6: The leucocyte adhesion cascade
Leucocyte adhesion is a stepwise process. First, cells loosely attach to the endothelium (tethering) and
start rolling on the EC. These first interactions are mainly mediated by selectins. By binding of integrins,
the cells firmly adhere and are able to transmigrate through the vessel wall into inflamed tissues.
For the specific interactions between leucocytes and activated EC, many adhesion
molecules need to be expressed. The most important ones on both cell types are listed
in table 1.3 and further described in the following paragraph.
EC Leucocyte Process
E-selectin PSGL1, CD44,
ESL1
rolling
PSGL1 L-selectin rolling
VCAM1 VLA4
(β1-integrin)
firm adhesion
ICAM1 LFA1
(β2-integrin)
firm adhesion
Table 1.3: Adhesion molecules and ligands on EC and leucocytes
At first, the leucocytes loosely attach to the EC (tethering) and start rolling on
the EC layer. These initial steps are predominantly mediated by a set of specific
selectins. Selectins are type I membrane glycoproteins, binding to these receptors
is dependent on the glycosylation of the ligand [33]. Three different selectins are
important for leucocyte adhesion: L-selectin which is expressed by leucocytes, P-
selectin and E-selectin which are expressed by inflamed EC. The dominant interac-
tion partner of all three selectins is the P-selectin ligand 1 (PSGL1), but this is only
functionally when it is glycosylated correctly. Other known glycosylated ligands for
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E-selectin are CD44 and E-selectin ligand 1 (ESL1) [32, 33]. It has been shown that
L-Selectin and P-selectin require shear stress for binding as the rolling cells detach
when the flow is stopped [34, 35, 36]. The binding of selectins to their ligands in-
duces downstream signaling on both sides, but these signaling pathways are not well
understood yet [32].
After being activated, the immune cells adhere firmly and are able to transmi-
grate through the vessel wall into the surrounding tissue. The transmigration can
occur by two distinct mechanisms, the cells enter either via para- or transcellular
routes. The paracellular route is described as the migration of leucocytes between
two EC through endothelial junctions, the transcellular route is through one cell by
intracellular channels [32]. These leucocyte - EC interactions during the adhesion
cascade are mainly driven by binding to integrins and by the signaling through sev-
eral chemokines. Integrins are heterodimeric glycoprotein receptors that consist of
two non-covalently bound α and β subunits [37]. There are 18 α and 10 β subunits
known so far, which can combine to 24 distinct integrins [38]. One example expressed
by leucocytes is Very Late Antigen 4 (VLA4), an α4β1-integrin that is able to bind
to Vascular Cell Adhesion-Molecule 1 (VCAM1) on EC. Another β2-integrin ex-
pressed on leucocytes, Lymphocyte-Function associated Antigen 1 (LFA1) binds to
Inter-Cellular Adhesion Molecule1 (ICAM1), mediating the firm adhesion of leu-
cocytes [32]. It is important to note that the glycosylation of the integrin receptor
plays an essential role in the function of the protein. In many tumors integrin gly-
cosylation can be altered, leading to changes in adhesion and migration properties
[39].
There are some molecules that have been shown to be of particular interest in
MM homing. MM cells express CD44 and VLA4, which are both known receptors
involved in leucocyte homing (see above) [11]. VLA4 is able to bind fibronectin
in the BM ECM and VCAM-1 on BMSC. The binding of BMSC can trigger IL-6
secretion, a factor promoting MM cell survival and proliferation [10, 12]. The highly
expressed surface proteoglycan Syndecan-1 (CD138), which is a marker for plasma
cells and at the same time is used as a marker for MM, binds also to the ECM. This
transmembrane heparan sulfate bearing proteoglycan is expressed in most MM cells
and able to bind to type I collagen [11]. BMSC express stromal-cell derived factor-1
(SDF1), which is the ligand for CXCR4 expressed on the MM cells. Besides its role
in B-cell migration and proliferation, CXCR4 plays also an important role in MM
homing. SDF-1/CXCR4 mediated adhesion promotes transendothelial migration of
MM cells by upregulation of VLA-4/VCAM-1 [40, 41].
In addition to the expression of several adhesion molecules, MM cells express and
secrete a variety of chemokines and chemokine receptors, influencing migration and
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homing [40]. One example is the macrophage inflammatory protein 1 α (MIP-1α),
which seems to be involved in the induction of lytic bone lesions and is additionally
able to stimulate proliferation, migration and survival of MM cells in the BM.
1.3 (Ga)lectins in MM - EC interactions
Glycans (complex carbohydrates) are major components of the outer cell surface
and are attached to proteins via N- or O-linkage by an enzymatical process. EC
glycosylation can be heavily altered in the tumor situation displaying or masking
ligands for endogenous lectins. Both, selectins as well as integrins are glycosylation
dependent and adhesion is influenced by alterations in their glycosylation patterns or
the glycosylation of their ligands [42, 43]. During malignant transformation, tumor
cells change their glycosylation patterns promoting tumor progression and metas-
tasis. Common tumor cell epitopes are sialyl-Lewisx, sialyl-Lewisa (sLex, sLea ),
Thomsen-Friedenreich (T or TF) antigen (CD176), Thomsen-nouvelle antigen (Tn;
CD175) or sialyl-Tn (sTn; CD175s). Enhanced sLex/a expression correlates with an
increased adherence to E-selectin [43]. Besides its influence on tumor adhesion pro-
cesses, angiogenesis can also be influenced by altered glycosylation patterns. Gal-1,
a member of the galectin family, has recently been shown to associate with glycosy-
lated EC receptors influencing the resistance of tumors to anti-VEGF therapy [44].
It can be presumed that also other lectins can influence MM-EC interactions to
promote angiogenesis in the tumor microenvironment. For MM it has been shown
that the glycome is altered in many different ways during disease progression [45].
Lectins are defined by their selective binding to carbohydrates but they do not
have any enzymatic activity. Originally they were classified as either C-type lectins
(Ca2+ dependent) or S-type lectins, which are today known as galectins [46, 47].
By binding to surface carbohydrates, they “sense” the glycosylation patterns of cells
and are able to induce signaling pathways.
Galectins represent a group of mammalian lectins which specifically bind β-
galactosides [48]. Galectins are very conserved among species and can even be
found in plants and fungi [49]. Today, 15 different mammalian galectins are known.
Galectins consist of at least one carbohydrate recognition domain (CRD) and are
further classified according to their structure [49, 50, 51]. Galectins that consist of
only one CRD are termed prototype galectins (Gal-1, -2, -5, -7, -10, -11, -13, -14
and -15), whereas galectins consisting of two CRDs joined by a linker are named
tandem repeat galectins (Gal-4, -6, -8, -9 and -12). One exception is Gal-3, which is
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a so-called chimera galectin consisting of one CRD fused to a amino-acid tail (Fig-
ure 1.7). Each galectin has different sugar-binding specificities due to differences of
amino acids in the binding pocket of the CRD.
Prototype Chimeric Tandem-repeat
1, 2, 5, 7, 
10, 11, 13,
14, 15
3 4, 6, 8, 9, 12
Figure 1.7: Galectins - classification
Galectins can be classified according to their structure in prototype galectins with one CRD, tandem repeat
galectins with two CRDs joined by a linker and chimera galectins containing one CRD fused to an amino
acid tail. (Figure according to Leﬄer et al. [50])
Prototype galectins such as Gal-1 and -7 have been shown to exist as dimers in
solution, Gal-3 precipitates as a pentamer [52, 53]. This leads to bi -or multivalent
molecules capable of binding more than one carbohydrate ligand. Tandem-repeat
galectins occur per se as bivalent molecules which can possibly bind more than one
ligand. For Gal-1 and Gal-3 it has been shown, that they are able to cluster receptors
on T-cells to induce downstream signaling [54, 55, 56]. Additionally, multimerization
on the cell surface of Gal-3 was visualized using fluorescence resonance energy trans-
fer (FRET) [57]. Those observations lead to the suggestion of a model by Rabinovich
and Toscano [58] that galectins form glycan-protein lattices on the cell surface in
order to induce receptor clustering and downstream signaling (Figure 1.8) [58, 59].
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interaction on the cell surface
Figure 1.8: Formation of galectin-glycan lattices
Prototype galectins exist as monomers or dimers, chimeric Galectin-3 as mono-or pentamer. Those di-
or multimers, as well as the tandem-repeat galectins (which already consist of two CRDs) are able to
bind glycans on the cell surface and thereby crosslink cell surface receptors. (Figure modified according to
Rabinovich et al. [58])
So far there is not much experimental evidence that these processes really oc-
cur for all known galectins besides Gal-1 and Gal-3 [54, 55, 56, 57]. In particular,
not much is known about di- or multimerization of tandem-repeat galectins in the
absence or presence of a ligand. Artificial linkage of two Gal-1 CRDs by several link-
ing structures showed homodi - and multimerization by an artificial tandem repeat
galectin, but there is no experimental evidence that “real tandem-repeat galectins”
do so [60].
Galectins are ubiquitously expressed and can be found in the cytoplasm, on the
cell surface and in the extracellular microenvironment after secretion via an uncon-
ventional pathway [61]. They are involved in many different cellular processes like
cell-cell adhesion, apoptosis, angiogenesis and migration [59, 62]. Figure 1.9 gives an
overview of galectin-involved cellular events.
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Figure 1.9: Galectins - biological roles
Galectins can be involved in many different cellular processes. They can be found in the nucleus, in the
cytoplasm and on the cell surface. Secretion occurs by a non-classical secretion pathway. Binding to ligands
on the cell surface leads to receptor clustering followed by downstream signaling, cell-cell or cell-ECM
interactions.
Since galectins play a role in many basic cellular mechanisms, the dysregulation
of galectin-expression can have an impact on tumorigenesis [62, 63, 64]. Several
galectins are expressed in different tumor cells and tissues [64, 65]. The expression of
the different galectins is highly variable in different tumors, thus linking of galectin-
expression patterns to malignancy is difficult to achieve and has to be examined for
each tumor-type and galectin separately. Changes in the expression and subcellular
localization can occur during the transition of a normal cell to a cancer cell [63].
Gal-1 and -3 are the best studied galectins at the moment, but also Gal-8 seems to
be involved in tumor biology. Table 1.4 summarizes the impact of Ga-1, -3 and -8
on tumor development and progression.
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Effect on Reference
Gal-1 tumor transformation, binding H-Ras [66]
cell cycle regulation [67]
Gal-3 tumor transformation, binding K-Ras [68]
cell cycle regulation [69]
anti-apoptosis [70, 71]
signal transduction [72]
cell-matrix interaction [73]
Gal-8 modulation of cell adhesion [74]
binding of integrins [75, 76, 77, 78]
Table 1.4: Impact of Gal-1, -3 and -8 on tumor progression
In MM, Gal-1, -3 and -9 have so far been described to play a role in the progression
of the disease. Gal-1 supports the survival of MM cells by interaction with SDF-1
α [79], whereas Gal-3 is an anti-apoptotic factor in diffuse large B-cell lymphomas
[80]. Furthermore, Gal-9 seems to have a rather inhibitory effect on the growth of
cancer cells and leads to apoptosis in MM [81]. Additionally, in a first study it
was shown, that the anti-Gal-3 compound GCS-100 could be used as a therapeutic
molecule against MM. It modified intracellular signaling leading to an inhibition of
proliferation and apoptosis [82]. This implies that galectins can be new targets for
anti-myeloma therapy. The effect of other galectins on MM has not been investigated
yet.
1.3.1 Galectin-8
Gal-8 was first described in 1995 as a rat lectin related to Gal-4 [83]. In 2000, it was
found in humans as a surface marker associated with prostate cancer and named
prostate carcinoma tumor antigen-1 (PCTA-1) [84]. Thereafter is was shown that
PCTA-1 is a galectin that belongs to the family of tandem-repeat galectins consisting
of two CRDs connected by a linker region and thus its name was changed to Gal-8.
By alternative splicing, isoforms with differences in the length of the linker region
are created [65, 84]. The linker of Gal-8 short (Gal-8S) consists of 34 amino acids
whereas the Gal-8 long (Gal-8L) isoform linker consists of 76 amino acids. Gal-8 is
expressed in many healthy and tumor tissues of different origins [65, 85, 86, 87, 88].
Depending on the tumor, Gal-8 is either increased or decreased in the progression
of the disease [64, 65, 74, 87, 89, 90, 91, 92, 93].
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As expected for a lectin with two CRDs, both domains are able to bind dis-
tinct glycan structures. The N-terminal CRD seems to have in general a higher
binding affinity compared to the C-CRD [94]. The N-CRD prefers sialylated and
sulfated oligosaccarides, whereas the C-CRD seems to prefer non-sialylated glycans
like blood-group A and B antigen or polylactosamine [94, 95, 96, 97, 98, 99].
Although not much is known about the function of the lectin, it seems to play a
role in the induction of apoptosis on different leucocytes [98, 100]. Furthermore, a
pro-angiogenic role on bovine aortic endothelial cells (BAEC) has been shown [101].
Stimulation of EC with recombinant Gal-8 induces the secretion of pro-angiogenic
cytokines and the expression of certain adhesion molecules [89]. Several studies dis-
play the lectins role in adhesion processes by binding of integrins [75, 76, 77, 78]
and that it strengthens the adhesion of colon cancer cells to EC [74]. Recent publi-
cations report a critical role of Gal-8 in the defense of bacterial infections indicating
the involvement of Gal-8 in the immune system [102, 103]. Still many questions are
open regarding the function of Gal-8 and not much is known whether both isoforms
have different effects on the biological functions. Only few studies deal with both
isoforms, mostly the short-linker isoform has been used for published experiments
so far.
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1.4 Aim of the study
This study intends to investigate the role of Gal-8 in the progression of MM. Nothing
is known yet about the influence of Gal-8 in MM, but there is some evidence that Gal-
8 plays a role in angiogenesis as well as in adhesion processes. Since MM progression
depends on both, tumor-angiogenesis and homing of the malignant cells into the
bone marrow, I was wondering, whether Gal-8 plays a key role in the progression of
the disease. In my study, I wanted to see whether the length of the linker influences
the biological function of Gal-8. The linker region seems to have an impact on the
function of the lectin [104], however the long-linker isoform has not been considered
in most studies about Gal-8 function.
In a first step, the influence of Gal-8 expression in MM patients was analyzed using
Gal-8 expression data from bone-marrow biopsies. It was important to investigate if
Gal-8 is expressed in MM and if expression of the lectin differs during the progression
of the disease or if it correlates with survival prognosis.
After preliminary tests, the study was divided into three different sub-projects,
each focussing on different aspects of Gal-8 in MM biology. The working plan for
my thesis was as follows:
1. Gal-8 in (tumor-) angiogenesis
Since MM progression is depending on tumor-angiogenesis, the impact of recombi-
nant Gal-8 on angiogenesis was examined first. In order to find out if Gal-8 plays
a critical role in this process the effect of Gal-8 on proliferation and migration in
EC was examined. Additionally, an in vitro tube formation assay was performed, to
detect if Gal-8 has any pro-angiogenic potential.
2. Gal-8 in MM homing
A second aspect in MM progression is the adhesion of MM cells to EC in the BM.
In order to find out if Gal-8 is a factor promoting adhesion of MM to EC, an in
vitro shear stress model was established. The influence of recombinant and MM cell
derived Gal-8 on MM EC interaction was studied using this system.
3. Gal-8 multimerization
Dimerization and lattice formation has only been shown for prototype galectins and
the chimeric Gal-3 so far. Using a new technique, microscale thermophoresis (MST),
the capability of Gal-8 to built dimers or multimers was studied.
2Materials & Methods
2.1 Materials
2.1.1 Primary Antibodies
Specificity
(Clone)
Species Isotype Conjugate Supplier Application
Anti-human
CD31
mouse IgG1 APC RnD FACS
Anti-human
CD31
mouse IgG1 unconjugated Dako tube formation
assay
Anti-human
CD38
mouse IgG1 FITC BD Biosciences FACS
Anti-human
CD54
mouse IgG1 APC BD Biosciences FACS
Anti-human
CD56
mouse IgG1 APC BD Biosciences FACS
Anti-human
CD59
mouse IgG2A FITC BD Biosciences FACS
Anti-human
CD62e
mouse IgG2A PE Biolegend FACS
Anti-human
CD138
mouse IgG1 PE BD Biosciences FACS
Anti-human
CD144
mouse IgG2B PE RnD FACS
Anti-human
W6/32
mouse IgG unconjugated Dr. Gerd
Moldenhauer
[105]
FACS
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Specificity
(Clone)
Species Isotype Conjugate Supplier Application
Anti-human
Gal-8
mouse IgG2A unconjugated RnD ELISA, IP
Anti-human
Gal-8
goat IgG
polyclonal
biotin RnD Western Blot,
ELISA
2.1.2 Secondary Antibodies
Specificity (Clone) Species ConjugateSupplier Application
Anti-mouse IgG+IgM goat APC Dianova FACS
Streptavidin APC Dianova FACS
Streptavidin FITC BD
Biosciences
FACS
Streptavidin POX Dianova Western Blot,
ELISA
2.1.3 Lectins
Galectins were kindly produced and provided by Prof. Hans-Joachim Gabius (LMU
Munich) as described in the methods section.
Name Specificity Conjugate Supplier Application
Arachis hypogaea
Peanut Agglutinin
(PNA)
Galβ1-3GalNAcα1-
Ser/Thr
biotin Linaris/Vector
Laboratories
FACS
Maackia amurensis
lectin II (MAA)
Neu5Ac/Gcα2,3
Galβ1, Glc(NAc)
biotin Linaris/Vector
Laboratories
FACS
Sambucus nigra
(Elderberry) bark
lectin (SNA)
Neu5Acα2-
6Gal(NAc)-R
biotin Linaris/Vector
Laboratories
FACS
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2.1.4 Enzymes
Enzyme Supplier
α-2-3,6,8 Neuraminidase from Vibrio cholarae
(VCN)
Roche
2.1.5 Cell lines
Name Origin Supplier
HBMEC-60 bone marrow endothelium Sanguin, Amsterdam
HUVEC umbilical vein endothelium Promocell
LP-1 peripheral blood of a MM
patient
DSMZ
MOLP-8 peripheral blood of a MM
patient
DSMZ
NHDF adult breast skin (female) Promocell
2.1.6 Sera
Sera from 42 MM patients were kindly provided by Drs. Anja Seckinger
(Heidelberg) and Dirk Hose (Heidelberg).
2.1.7 Cell culture media and supplements
Medium / supplement Supplier
AIM-V + AlbuMax (BSA) 1x Gibco
Detach Kit Promocell
Dulbeccos modified eagle medium (DMEM) Sigma
Endothelial cell basal medium (ECBM) Promocell
Endothelial cell growth medium supplement pack Promocell
Fetal bovine serum (FBS) Biochrome
Freezing medium Ibidi
HEPES Gibco
MEM non-essential amino acids (NEAA) PAA
RPMI-1640 AQmedia Sigma
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2.1.8 Kits
Kit Supplier
2x buffer SYBR green Applied Biosystems
Dako LSAB2 System Hrp Dako
High pure RNA isolation kit Roche
Monolith NT.115 labeling kit red NHS Nanotemper
Pierce BCA Protein Assay Kit Thermo Scientific
Pierce Classic IP Kit Thermo Scientific
Platinum Blue PCR Mix Invitrogen
Super Script first strand cDNA synthesis system for
RT-PCR
Invitrogen
Super Signal West Dura Extended duration
substrate
Thermo Scientific
TMB substrate kit Thermo Scientific
VenorGeMOneStep PCR kit Minerva
2.1.9 Molecular weight markers
Marker Supplier Application
Gene ruler 100bp Fermentas DNA agarose gel electrophoresis
Rainbow marker full range GE Healthcare SDS gel electrophoresis
2.1.10 PCR primer for qRT-PCR
qRT-PCR primers were purchased from MWG operon and stocks were diluted to a
concentration of 200µM in ddH2O. Frozen stocks were thawed and further diluted
to a concentration of 5µM prior to use.
Primer Sequence
β-Actin fwd 5’- GCT CCT CCT GAG CGC AAG -3’
β-Actin rev 5’- CAT CTG CTG GAA GGT GGA CA -3’
Gal-8 fwd * 5’- CTT AGG CTG CCA TTC GCT -3’
Gal-8 rev * 5’- AAG CTT TTG GCA TTT GCA -3’
CD54 fwd 5’- GGG CAT AGA GAC CCC GTT GCC T -3’
CD54 rev 5’- GGG TGC CAG TTC CAC CCG TTC -3’
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Primer Sequence
CD31 fwd 5’- ATT GCA GTG GTT ATC ATC GGA GTG -3’
CD31 rev 5’- CTC GTT GTT GGA GTT CAG AAG TGG -3’
CD62e fwd 5’- ATC CAA AAG GCTCCA ATG TG -3’
CD62e rev 5’- CTC CAA TAG GGG AAT GAG CA -3’
CD144 fwd 5’- CGA TAC ATG AGC CCT CCC GCG -3’
CD144 rev 5’- GAT CTG CAG GAC CAG CTG GAA AA -3’
* primer sequence according to Thijssen et al. [88]. All other primers were de-
signed according to their mRNA sequence and the specificity of the primers was
checked using NCBI/ Primer-BLAST.
2.1.11 PCR primer
PCR primers were purchased from MWG operon and stocks were diluted to a con-
centration of 200µM in ddH2O. Frozen stocks were thawed and further diluted to a
concentration of 20µM prior to use.
Primer Sequence
Gal-8 fwd * 5’- AGA ATG ATG TTG TCC TTA AAC -3’
Gal-8 rev * 5’- CTA CCA GCT CCT TAC TTC C -3’
* primer sequence according to Thijssen et al. [88]. The specificity of the primers
was checked using NCBI/ Primer-BLAST.
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2.1.12 Buffers & solutions
Application Buffer Contents Molarity/
grams
ELISA Coating buffer (pH9.6) Na2CO3 0.52g
Tween-20 0.05% (v/v)
ddH2O 100ml
adjust pH with
NaHCO3
Wash buffer PBS
Tween-20 0.05% (v/v)
Western Blot Blotting buffer (pH7.5) Trizma base 25mM
NaCl 0.15M
Tween-20 0.05% (v/v)
adjust pH with HCl
Blocking buffer non-fat dry milk 2% (w/v)
in Blotting buffer
Antibody incubation buffer non-fat dry milk 1% (w/v)
in Blotting buffer
Transfer buffer 1 (pH9.4) Aminocaproic acid 0.04M
Trizma base 0.025M
adjust pH with HCl
Transfer buffer 2 (pH10.4) Trizma base 0.3M
adjust pH with HCl
Transfer buffer 3 (pH10.4) Trizma base 0.025M
adjust pH with HCl
Galectin
dissolving
buffer
10mM PB-buffer (pH7.2) 0,2M NaH2PO4 1.4ml
0,2M Na2HPO4 3.6ml
ad ddH2O 100ml
FACS FACS buffer PBS
BSA 1% (w/v)
NaN3 0.1% (w/v)
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Application Buffer Contents Molarity/
grams
SDS Gel-
electrophoresis
10x SDS running buffer Trizma base 151.5g
Glycine 720g
ad ddH2O 5l
ThermophoresisMST-optimized buffer (pH
7.2)
Trizma base 50mM
NaCl 150mM
MgCl2 10mM
Tween-20 0.05% (v/v)
BSA 0.1% (w/v)
adjust pH with HCl
PCR 50x TAE buffer (pH 8.3) Trizma base 2M
Acetic acid
(anhydrous)
1M
EDTA 100mM
adjust pH using
acetic acid
(anhydrous)
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2.1.13 Chemicals
Chemical Supplier
16% Paraformaldehyde solution (PFA) Thermo Scientific
[3H]-Thymidine PerkinElmer
6x DNA gel loading buffer Novagen
7-Amino-Actinomycin-D (7-AAD) viability probe BD Biosciences
Acetic acid (anhydrous) Merck
ADEFO Citroline 2000 Adefo
Adefofix-Fixierer Adefo
AEC+ high sensitivity substrate Dako
Albumin standard Thermo Scientific
Aminocaproic acid Sigma
Ammonium persulfate (APS) Sigma
Beta-lactose minimum 99% total lactose Sigma
Betaplate Scint Perkin Elmer
Blotto non-fat dry milk Santa Cruz/Chem Cruz
Bovine serum albumin (BSA) fraction V PAA
Calcein green AM Invitrogen
Dako fluorescent mounting medium Dako
Di-Sodium Hydrogenphosphate (Na2HPO4) Merck
Dimethyl Sulfoxide (DMSO) Eurolone
Dithiothreitol (DTT) Sigma
Ethanol Sigma
Ethidiumbromide solution 0,07% AppliChem
Ethylenediaminetetraacetic acid (EDTA) Acros
Gelatine from bovine skin type B Sigma
Glycerine AnalR Normapur
Glycine Sigma
Hydrochloric acid (HCl) 37% Normapur
Hydrocortisione acetate Sigma
Hydrogen peroxide (H2O2) Sigma
Isopropanol (2-Propanol) J.T.Baker
LDS sample buffer Expedeon
Magnesium chloride (MgCl2) Sigma
Methanol Sigma
N,N,N’,N’-Tetramethylendiamin (TEMED) Roth
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Chemical Supplier
Phosphate buffered saline (PBS) Sigma
PBS + Ca2/Mg2 Sigma
Protease-Phosphatase Inhibitor Cocktail Thermo Scientific
Protein A/G Plus Agarose Santa Cruz
recombinant human TNF-α PromoKine
recombinant human VEGF-165 Thermo Scientific
Roti-Load 1 protein loading buffer reducing Roth
Rotiphorese Gel 30 (Acrylamide/Bis) Roth
RunBlue RAPID SDS Run Buffer Expedeon
Silicon paste Roth
Sodium azide (NaN3) Merck
Sodium carbonate (Na2CO3) Merck
Sodium chloride (NaCl) Sigma
Sodium di-hydrogenphosphate (NaH2PO4) Merck
Sodium dodecyl sulfate (SDS) Powder GERBU
Sodium hydrogencarbonate (NaHCO3) Roth
Sodium hydroxide (NaOH) Isochim
Sulfuric acid (H2SO4) Roth
Triton-X 100 Sigma
Trizma base Sigma
Trypan blue Biochrom
Tween-20 Sigma
Ultra Pure Agarose Invitrogen
Water, DNase, RNase free MP Biomedicals
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2.1.14 Consumables
Sterile plastic-ware for cell culture was ordered from TPP or BD Biosciences if not
indicated otherwise.
Consumable Supplier
1x8 Stripwell plates high binding Costar
24-well cell culture cluster Costar
3mm Chr blotting paper NeoLab
96-well qRT-PCR plate StarLab
Amersham Hyperfilm ECL GE Healthcare
Amicon Ultra-15 Millipore
C-Chip disposable hemocytometer DigitalBio
Cell Scraper 320mm CytoOne
Cellulose chromatography paper Whatman
Cryo.S Greiner bio One
Culture-inserts for self-insertion Ibidi
HumanHT-12 v4 Expression BeadChip Illumina
MicroAmp Optical Adhesive Film Life Technologies
Millex GP filterunit 0.22µM Millipore
NT.115 hydrophobic capillaries Nanotemper
Nunc MicroWell 96-well plates Thermo Scientific
Parafilm “M” Sigma
Perfusion set red Ibidi
Perfusion set white Ibidi
Petri dishes 35x10mm Falcon
Printed filtermat A Perkin Elmer
RunBlue SDS precast gels 4-12% Expedeon
Safe lock tubes 0.5ml; 1.5ml; 2ml Eppendorf
Sample bag for MicroBeta Perkin Elmer
Serial connector Ibidi
Superdex 200 HR 10/30 column GE Healthcare
Syringe 50ml without needle Terumo
Transfer membrane Immobilion-P Millipore
µ-Slide 8-well ibiTreat Ibidi
µ-Slide angiogenesis ibiTreat Ibidi
µ-Slide I0.6 ibiTreat Ibidi
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2.1.15 Instruments
Instrument Manufacturer
-20°C freezer comfort Liebherr
-80°C freezer Hera freeze Thermo Scientific
+4°C fridge Profiline Liebherr
7300 Real Time PCR System Applied Biosystems
Agarose-Gel-electrophoresis system Hybaid
Allegra 218 centrifuge Beckman
Cell Observer.Z1 Zeiss
Chicken egg incubator Termo-de-Luxe 150 J. Hemel Brutgeräte
Dyad DNA engine BioRad
FACS CantoII BD Biosciences
Heracell 204i CO2 incubator Thermo Scientific
Heraeus Fresco17 centrifuge Thermo Scientific
Herasafe clean bench Heraeus
Leica DM IL LED Leica Microsystems
Leica TCS SP5 II Leica Microsystems
Liquid nitrogen tank Cryotherm
MicroBeta TriLux Perkin Elmer
Microwave oven Sharp
MilliQ water purification systems Millipore
Monolith NT.115 Nanotemper
Mr. Frosty Thermo Scientific
Multi image light cabinet HeroLab
Multiscan EX Thermo Scientific
Nanodrop 2000 Thermo Scientific
Optimax X ray film processor PROTEC Medizintechnik
PEQ Power 300 PeqLab
pH meter pH525 WTW
Pipet boy Integra
Pipettes 1000µl; 200µl; 100µl; 10µl; 2,5µl Eppendorf
Promax 2020 Heidolph
Pump system Ibidi
Rotana 460RC Hettich Zentrifugen
SDS-chamber model V15.17 Biometra Analytik Jena
Stereomicroscope SMZ 800 Nikon
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Instrument Manufacturer
Thermomixer Comfort Eppendorf
TomTec Harvester SisLab
Viscotek TDAmax Malvern
Water bath Medingen E5
Western Blot transfer chamber LTF Labortechnik
2.1.16 Software
Software Supplier
Adobe Illustrator CS5 Adobe Systems GmbH
Adobe Photoshop CS5 Adobe Systems GmbH
Angiosys 1.0 TCS (Cellworks)
Chipster The Finnish IT Center for Science CSC
Flow Jo 9.5.2 TreeStar
Igor Pro 6.3 Wave Metrics
Image J Wayne Rasband (NIH)
Office 2008 Microsoft Corporation
Prism 5 GraphPad Software Incorporated
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2.2 Methods
2.2.1 Cell culture
All cells were cultivated under sterile conditions at 37°C and in a 5% CO2 atmo-
sphere.
Human umbilical vein endothelial cells (HUVEC) and human bone marrow endothe-
lial cells (HBMEC-60) were cultivated in endothelial cell basal medium (ECBM)
supplemented with 10% FBS and growth factors. Cells were split twice per week
and used in passage 4 or 5 (HUVEC) or up to passage 20 (HBMEC-60).
Normal human dermal fibroblasts (NHDF) were cultivated in Dulbeccos modified
Eagle medium (DMEM) supplemented with 10% FBS, 1% non-essential amino acids
(NEAA) and 1% HEPES. Medium was changed twice weekly, cells were split every
7-14 days (depending on confluency) and used until passage 15.
Adherent cell lines were detached using the detach kit containing HEPES for wash-
ing, Trypsin/EDTA for detaching and Trypsin-neutralizing solution (TNS).
The MM cell lines MOPL-8 and LP-1 were cultivated in RPMI containing 20% or
10% FBS respectively. Cells were split twice per week and used in passage up to
passage 20.
Cells were counted diluting them 1:2 with trypan-blue for live-dead discrimination
using a Neubauer counting chamber.
For cryoconservation, cells were adjusted in freezing medium to 1x106/ml (adherent
cells) or to 3x106/ml (suspension cells) and frozen at -80°C using a Mr. Frosty
according to the manufacturers protocol. Long-term storage was performed in a
liquid nitrogen tank.
The cells were mycoplasma free as determined by the VenorGeMOneStep PCR kit.
Multiplexion human cell line authentication test (MCA) was performed as described
(www.multiplexion.de). Both MM cell lines are included in the MCA data base.
Identity was confirmed to 100%, no cross-contamination with other cell lines was
found. For HBMEC-60 a HeLa contamination was excluded, but the identity could
not be confirmed, because the cell line is not included in the MCA database.
2.2.2 Preparation of cell culture supernatants
For Gal-8 detection in cell culture supernatants 7.5x105EC or 2.5x106MM cells were
cultivated in the respective cell culture medium for 48h. Supernatants were cen-
trifuged at 300g, cellular debris was discarded and the supernatants were mixed
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with protease/phosphatase inhibitors.
Prior to shear stress experiments with conditioned supernatants, MOLP-8 cells
were pre-cultured in RPMI-1640 supplemented with 10% FBS for at least 3 days.
5x106cells were transferred to 20ml AIM-V Medium and cells were cultivated at
37°C in a 5% CO2 atmosphere for 72h. Supernatants were centrifuged at 300g, cel-
lular debris was discarded and the supernatants were concentrated 20-fold using an
Amicon Ultra-15 Centrifugal Filter Unit according to the manufacturer’s protocol.
Concentrated supernatants were supplemented with protease-phosphatase inhibitors
and subsequently used for Gal-8 depletion.
2.2.3 Gal-8 depletion in cell culture supernatants
Concentrated supernatants were used for the Gal-8 depletion. 1ml of 20x supernatant
was incubated with 5µg of anti-Gal-8 antibody (mouse monoclonal) over night at
4°C on a shaker. The following day the supernatants were incubated twice with
20µl Agarose A/G slurry for 30min. The mixture was centrifuged at 1000g and
the supernatants were taken for further shear stress experiments. Gal-8 content of
depleted cell culture supernatants was investigated using a Gal-8 specific ELISA.
2.2.4 Enzymatic treatment of cells
For VCN treatment, cells were diluted in RPMI-1640 and treated for 1h at 37°C with
5mU/5*106 cells. After the treatment, the cells were washed once with RPMI-1640
and used for further experiments.
2.2.5 Stimulation of cells with TNF-α
Cells were diluted in their regular cell culture medium and stimulated using 10ng/ml
TNF-α for 24h prior to an experiment.
2.2.6 Calcein-green staining of cells
5*106 cells of the respective MM cell line were washed once with PBS and diluted in
RPMI-1640 containing 1% HEPES. Cells were incubated with 5µM calcein-green for
30 minutes and washed twice with PBS afterwards. The stained cells were diluted
in the respective medium needed for the following experiments.
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2.2.7 Preparation of galectins
The preparation and lyophilization of galectins was kindly performed by Prof. Hans-
Joachim Gabius (LMU Munich) [99, 106]. Wild type and variant proteins were ob-
tained by recombinant production followed by chromatographic purification and
quality controls. Protein concentrations were determined using the theoretical mo-
lar adsorption coefficient before lyophilization. Galectins were stored at -20°C and
dissolved in 10mM PB buffer before use. Protein concentration after dissolving was
determined using a BCA assay. Diluted proteins were stored in aliquots at -20°C.
Proteins were not refrozen after thawing once.
2.2.8 BCA Assay
For quantification of protein-concentrations, the BCA assay was used. 10µl of the
lysate or the standard protein were loaded into the wells of a 96-well plate. Standard-
protein concentrations to calculate a calibration curve were ranging from 100µg/ml
to 1500µg/ml. For detection, 200µl of a 50+1 mixture of reagent A and reagent B
was added and the 96-well plate was incubated for 30min at 37°C. Absorption was
measured in an ELISA reader at 540nm.
2.2.9 RNA-isolation and cDNA synthesis
Total cellular RNA was isolated from 1x106 cells using the high pure RNA isolation
kit according to the manufacturer’s protocol. The concentration and purity of the
isolated RNA was determined using a Nano-Drop 2000. cDNA synthesis was per-
formed with 800ng RNA using the SuperScript First-Strand Synthesis System for
RT-PCR according to the supplier’s protocol.
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Reagents Volume/ concentration
RNA 800ng
dNTP mix (10mM) 1µl
Oligo(dt) 12-18 (0.5µg/µl) 1µl
water, DNase RNase free ad 10µl
incubate at 65°C for 5min, put subsequently on ice for 1min
10x RT buffer 2µl
MgCl2(25mM) 4µl
DTT (0.1M) 2µl
RNase OUT 1µl
incubate at 42°C for 2min
Superscript II RT (50U) 1µl
incubate at 42°C for 50min and subsequently for 15min at 72°C
RNaseH 1µl
incubate at 37°C for 20min, use immediately or store at -20°C
2.2.10 Real-time PCR
Real-Time PCR was performed on a 7300 Real Time PCR System using SYBR-green
PCR Master mix. Each cDNA probe was measured in triplicates.
Reagents Volume PCR cycle time (min)
2x buffer SYBR green 12.5µl 50° 2min (only at
1st cycle)
primer forward (fwd)
(5µM)
3µl 95°C 10min (only at
1st cycle)
primer reverse (rev) (5µM) 3µl 95°C 15sec
water, DNase RNase free 4µl 60°C 1min
cDNA 2.5µl repeat cycles
40 times
add dissociation stage
95°C 15sec
60°C 1min
95°C 15sec
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To calculate the gene expression relative to ß-actin, the cycle threshold (Ct) value was
determined for each primer pair. The Ctvalue defines the cycle in which the sample
fluorescence intensity overcomes the background fluorescence. This value can be used
for relative quantification of the sample. Calculation of the relative expression level
of the gene of interest (gene x), was performed using the ∆Ctmethod with following
equation:
∆Ct = x¯C
β−actin
t − x¯C gene xt
The standard deviation was calculated with the following formula:
STDEV4Ct =
√
(STDEV C β−actint )2 + (STDEV Ct gene x)2
To compare relative expression levels of different genes, the ∆Ctlevels of the respec-
tive genes were normalized to a control treated sample.
2−44Ct with 44Ct = 4C controlt −4Cgene xt
The normalized standard deviations were calculated as:
+STEDV = 2−44Ct + STEDV 4Ct
−STEDV = 2−44Ct − STEDV 4Ct
2.2.11 PCR
For Gal-8 full-length PCR 2µl of cDNA was mixed with the Gal-8 PCR primers and
added to the Platinum Blue PCR Super Mix. Cycles were performed as suggested
by the supplier on a DNA engine Dyad thermal cycler.
Reagents Volume PCR cycle time
Platinum blue PCR
Super Mix
45µl 94°C 1min (only at
1st cycle)
cDNA 2µl 94°C 30sec
primer fwd (20µM) 0,5µl 55°C 30sec
primer rev (20µM) 0,5µl 72°C 90sec
water, DNase RNase free 2µl repeat cycles
30 times
72°C 10min
Products were loaded on a 2% Agarose gel and run using 1x TAE buffer. Products
were visualized using Ethidium Bromide.
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2.2.12 Whole genome expression analyses
2.2.12.1 Affymetrix
For whole genome analysis of MM patients and MM cell lines, the Affymetrix pro-
tocol was used. The data was obtained from Dr. Dirk Hose (Heidelberg) and used
for expression and survival analyses [107, 108, 109, 110].
2.2.12.2 Illumina
Whole genome expression analyses of HUVEC was performed using an Illumina
HumanHT-12 v4. RNA was isolated from the cells as described above and pro-
cessed according to the manufacturers protocol. Raw data were then obtained from
the DKFZ Genomics and Proteomics Core Facility and results were analyzed using
Chipster software.
2.2.13 Immunoprecipitation
Immunoprecipitation (IP) was performed using the Thermo Scientific Pierce Clas-
sic IP Kit. Either 5x106 HUVEC or 2x107 MM cells were lysed in 1x lysis buffer
containing protease and phosphatase inhibitors. After 5 min incubation on ice, in-
soluble cellular debris was removed by centrifugation at 13.000g for 10 min. Protein
concentration of the lysate was measured via BCA assay reagent and 1mg protein
was used for the IP. The IP was performed according to the manufacturer’s proto-
col using 3µg of anti-Gal-8 antibody (mouse monoclonal). The eluate was used for
western blot analysis against Gal-8.
2.2.14 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE)
Following the IP, proteins of the whole eluate from the IP (50µl) were separated
using 15% SDS-PAGE gels.
Resolving gel
reagents
Volume Stacking gel
reagents
Volume
ddH2O 7.35ml ddH2O 6.1ml
1,5M Tris/HCl pH8,8 7.5ml 0,5M Tris/HCl pH6,8 2,5ml
Acrylamide/Bis 15ml Acrylamid/Bis 1.33ml
TEMED 15µl TEMED 10µl
APS 10% 150µl APS 10% 50µl
SDS-Gels were loaded and electrophoresis was performed at 50mA constant in 1x
SDS-running buffer.
For multimer gels of recombinant galectins, 2µg protein was loaded using 4x LDS
sample buffer on 4-12% MOPS/SDS precast gels.
To determine protein-size, rainbow full range protein marker was loaded on the gels
in parallel.
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2.2.15 Western Blot analysis
Proteins separated on a SDS-PAGE were blotted on a Immobilion-P membrane using
semi-dry blotting technique. The membrane was activated by rinsing with methanol
followed by rinsing with transfer buffer 3. Six Whatman paper sheets were soaked
with transfer buffer 2 and put on the anode (+) side of a transfer chamber. Three
Whatman paper sheets soaked with transfer buffer 3, the Immobilion-P membrane
and the SDS gel rinsed with transfer buffer 3 were put on top. These were covered
with nine Whatman paper sheets soaked with transfer buffer 1. The cathode (-)
was put on top of the filter system. For transfer of proteins to the Immobilion-P
membrane, 0,8mA/cm2were applied for 1h.
After the transfer, the membrane was blocked in blocking buffer followed by 5x
10min washing in blotting buffer, incubation with biotinylated anti-Gal-8 antibody
at RT for 1 hour. The membrane was washed again 5x10min in blotting buffer and
incubated with Streptavidin-POX (1:50.000) followed again by 5 washing steps for
10min each in blotting buffer. The proteins were visualized using a x-ray film proces-
sor after incubating the membrane with SuperSignal Chemiluminescent Substrate
for 5min.
2.2.16 FACS
For FACS analyses 5x105 cells were incubated on ice for 30min with respective
antibodies or lectins (table) followed by two washing steps in FACS-buffer. Detection
antibodies were incubated for 30min on ice followed by two washing steps in FACS-
buffer. Biotinylated antibodies or lectins were detected using Streptavidin-FITC.
Primary unconjugated antibodies were detected using a secondary antibody with a
fluorescently labeled conjugate appropriate for the species of the primary antibody.
For live-dead discrimination of cells, viaprobe (7-AAD) was used. Fluorescence was
measured using a BD FACS Canto II. Data was analyzed using FlowJo software.
Lectin / antibody concentration / dilution
biotinylated recombinant Gal-8N 200nM
recombinant Gal-8 (S, L) 200nM
Streptavidin-FITC 1:800
anti-Gal-8 mouse monoclonal 1:100
secondary antibody with a fluorescently labeled
conjugate
1:100
primary antibody with a fluorescently labeled
conjugate
1:100
biotinylated SNA/MAA/PNA 10µg/ml
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2.2.17 ELISA
High binding 96-well plates were coated with 2,5µg/ml anti-Gal-8 antibody (mouse
monoclonal) in coating buffer over night at 4°C. The plates were washed three times
with washing buffer and blocked for 1h with 1% gelatin in PBS. 50µl of samples
were incubated for 2h at room temperature followed by three washing steps using
washing buffer. Gal-8 was detected incubating with 0,6µg/ml biotinylated anti-Gal-
8 antibody at RT for 1h followed by 0,5µg/ml Streptavidin-horseradish peroxidase
(POX) for 20min. Peroxidase-activity was detected using TMB substrate following
the manufacturer’s instructions. The reaction was stopped using 50µl 2M H2SO4.
For quantification, increasing concentrations of recombinant protein (Gal-8S) diluted
in blocking buffer were used. Readout was performed on a ELISA plate reader
(Multiscan EX) with 450nm filters (substrate) and 540nm filters (background).
2.2.18 Tritium-thymidine proliferation assay
Cells were seeded in 96-well plates (MM 2.5x104/well; EC and NHDF 1.5x103/well)
and stimulated with the respective galectin at indicated concentrations for 24h. After
the incubated, 1µCi [3H]-thymidine/well were added for 8h. Adherent cells were
washed with HEPES (detach kit) and detached with trypsin/EDTA (detach kit) for
10min at 37°C. The 96-well plates were frozen at -20°C and thawn for harvesting
at 37°C. Transfer of the cells to filters was performed in a TomTec harvester. After
transfer, filters were dried in a microwave oven at 150°C for 2-3min at 600watt.
Radiation was visualized using Betaplate Scintillator and read out was performed
in a MicroBeta TriLux.
2.2.19 Gap-closure assay
HUVEC were diluted to 3x105/ml in ECBM supplemented with 10% fetal bovine
serum, 1% HEPES and growth factors. 70µl of the solution were applied in each well
of a culture insert for self insertion in a chamber slide (ibi-treat). Cells were allowed
to grow for 24h at 37°C, in a 5% CO2 atmosphere. Then the culture insert was re-
moved and Gal-8 at indicated concentrations was added to the medium. Gap-closure
was monitored using a Zeiss Cell Observer.Z1 (objective: 5× / 0.16 EC Plan-NEO
Ph1 DIC0) with incubation chamber at 37°C in a 5% CO2 atmosphere. Pictures were
taken every 30min for 24h. Image Analyses was performed using ImageJ software
(http://www.le.ac.uk/biochem/microscopy/pdf/Wound%20healing%20assay.pdf).
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2.2.20 Tube formation assay
NHDF were seeded in 24-well plates and cultured for 5 days in DMEM supple-
mented with 10% fetal bovine serum, 1% HEPES and 1% non-essential amino acids.
HUVEC were seeded on the confluent NHDF layer and either VEGF-165 (concen-
trations ranging from 1.25ng/ml to 20 ng/ml) or the test compounds in concen-
trations as indicated were added to the respective wells. Growth medium including
growth factors and test substances was changed at day 3 of co-culture. At day 3 or
7 medium was removed from the co-culture, cells were washed and fixed in ice-cold
70 % ethanol (v/v) for 30 min at RT, followed by a washing step and incubation
in methanol/30% H2O2, 40:1 (v/v) for 10 min at RT. The cells were washed and
incubated with a monoclonal antibody against CD31 (1:40) for 30 min followed by
a washing step and incubated with a secondary goat anti-mouse IgG antibody cou-
pled to biotin (LSAB2) for 20 min. After further washing, the cells were incubated
for 20 min with streptavidin coupled to horseradish peroxidase (LSAB2). Antibody
reactivity was visualized by adding AEC-substrate to the cells for 14 min in the
dark. Enzymatic reaction was stopped by washing with water. Wells were sealed
with mounting medium and microscopic quantitative analysis (Leica DM IL LED)
of tube formation was performed with the software Angiosys 1.0.
2.2.21 Static adhesion assay
HUVEC were seeded in collagen-coated 48-well plates (1.5x104 cells/well) and grown
until confluency for three days. At the day of experiment, medium of HUVEC was
removed and 150µl ECBM supplemented with 1% HEPES and 200nM of the re-
spective galectin was added to each well. Calcein stained MM cells were diluted in
RPMI supplemented with 1% HEPES and 5x104 cells were added to the HUVEC in
a volume of 150µl medium. The final concentration was 100nM galectin/well. Cells
were allowed to adhere for 60min at 37°C, in a 5% CO2atmosphere and carefully
washed twice with pre-warmed PBS Ca2/Mg. 500µl of a mixture with equal volumes
of RPMI and ECBM supplemented with 1% HEPES was added and quantitative
observation of adherent cells was performed after microscopic observations (Zeiss
Cell Observer.Z1 (objective: 5× / 0.16 EC Plan-NEO Ph1 DIC0)) of each well. 2
photos per well were taken and analyzed using the ImageJ software.
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2.2.22 Shear stress assay
Pre-cultivation of HUVEC prior to the shear stress experiment was performed ac-
cording to IBIDIs application note 13 (http://ibidi.com/fileadmin/support/applica
tion_notes/AN13_HUVECs_under_perfusion.pdf). Briefly, 2.5 x 105 HUVEC were
seeded on a µ-Slide I0.6 Luer in 150µl endothelial cell basal medium supplemented
with 10% FCS and growth factors. After adhesion of cells to the µ-slide, the per-
fusion set red, filled with 12ml ECBM plus 10%FBS and growth factors, was con-
nected to the µ-slide. Cells were cultured with increasing shear stress for 24h (30min
2dyn/cm2; 30min 5dyn/cm2; 23h 10dyn/cm2). Prior to the shear stress experiment,
5 x 106 MM cells were stained with Calcein-green. Cells were resuspended in 25ml
RPMI + 25ml ECBM containing 1%HEPES. For each slide, 12 ml cell suspension
supplemented with the respective galectin was filled into a white perfusion set. MM
cells were perfused at 1dyn/cm2 for 30min and subsequently for 10min at 5dyn/cm2.
Images were taken on 4 different positions on each slide every 30sec using a Zeiss
Cell Observer.Z1 (objective: 5× / 0.16 EC Plan-NEO Ph1 DIC0). Adherent cells
were counted after microscopic observation using ImageJ.
2.2.23 Thermophoresis
Galectins were stained with a red fluorescent dye using nanotempers Protein Label-
ing Kit RED-NHS according to the manufacturer’s protocol. 10µM of the respective
galectin was mixed with 30µM of dye and incubated for 30min at RT in the dark. A
gravity column removed free dye from the labeled protein. For MST-measurement,
the labeled protein was kept constant at low concentrations (25nM) and mixed with
increasing concentrations of the unlabeled protein in MST-optimized buffer. Mea-
surements were performed in hydrophilic capillaries on a NanoTemper Monolith
NT.115 (60% LED; 40% IR-laser power). The curves were fitted with Hill kinetics
to obtain an EC50 and the dissociation constant for each Galectin. The software
IGOR pro was used for the fitting of the graphs.
2.2.24 Static light scattering
Static light scattering was performed by Vladimir Rybin (EMBL, Heidelberg). Static
light scattering (SLS) experiments were performed on a Viscotek TDAmax system,
equipped with Superdex 200 HR 10/30 column. As a mobile phase 1xMST buffer
without BSA and Tween-20 was used with a flow rate of 0.4 ml/min.
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2.2.25 Gal-8 modeling
The calculation as well as the description of the method were performed by Sonu
Kumar, Sanford-Burnham Medical Research Institute, San Diego.
The starting structures of short and long linker Gal-8 were retrieved from ModBase
server [111] using their fasta sequence. Gal-8 long linker structure used PDB ID:
3VKL [112]where as short linker used PDB ID: 4HAN [113] as template for mod-
eling. The template structure for linker is not available so it remained as extended
loop between N- and C- domains. To explore the structure of linker molecular dy-
namics simulations were performed on both the Gal-8 structures along with linker
in explicit solvent for 25 ns. For the simulations, the AMBER force field ff99SB was
used for the protein [114]. The structures were solvated in a box of TIP3P water
using periodic boundary conditions. Firstly, energy minimization was carried out for
removal of initial unfavorable contacts made by the solvent using 10000 minimiza-
tion cycles (500 steps of steepest descendent and 500 steps of conjugate gradient)
keeping protein backbone atoms restrained. Then, protein side chain atoms and ex-
plicit water molecules were kept unrestrained followed by unrestrained minimization
with 20000 cycles of the whole system. Secondly, the equilibration of the system was
carried out by heating the system slowly from 0 to 300 K for 300 ps, followed by
500 ps of maintaining 300 K constant temperature at constant pressure of 1 atm.
Then finally, production of dynamics were performed at 300 K for 25 ns using a 2-fs
time step, with the SHAKE algorithm at constant pressure of 1 atm. During the
simulations, SHAKE algorithm was turned on and applied to all hydrogen atoms
and the particle-mesh Ewald method was used for treating the electrostatic inter-
actions with a cutoff of 10 Å. Minimization, equilibration, and production phases
were carried out by the SANDER module of AMBER 8.
2.2.26 Statistics
2.2.26.1 General
If not indicated otherwise, Prism 5 was used to calculate statistics. Figures depict
mean +/- standard error of the mean (SEM). T-test was performed with the param-
eters: unpaired t-test, two-tailed, 95% confidence intervals. * p<0,05 / **p<0,01 /
*** p<0,001
2.2.26.2 Illumina Array
The expression data were normalized and log2 transformed by the Chipster soft-
ware. Heatmap analyses were performed using the standard settings for annotated
heatmap analyses in Chipster.
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2.2.26.3 Affymetrix Array
Expression data were gcrma-preprocessed and log2 transformed. From 6 Gal-8 spe-
cific probesets, probeset 2 was chosen for further analyses, since it showed best
correlation to overall survival. The probeset was validated by an independent co-
hort of patients treated within the total therapy 2 (TT2) or total therapy 3 (TT3)
protocol [115, 116].
Survival analyses (Kaplan-Meyer ) were performed according to standard settings
of the software Prism 5.
3Results
3.1 Gal-8 expression in MM and correlation to the
progression of the disease
It has been shown before that Gal-8 expression is altered in various types of cancers
in comparison to the corresponding healthy tissue. Depending on the tumor, Gal-8
is either increased or decreased in the progression of the disease [64, 65, 74, 87, 89,
90, 91, 92, 93]. No analyses are yet available which investigate the role of Gal-8 in
MM. In order to explore the role of Gal-8 in MM disease, I examined the expression
of the protein in patients serum and MM cells isolated from bone marrow biopsies.
The expression was correlated to patients’ survival by Kaplan-Meyer analysis and
chromosomal aberrations common in MM in order to find out if Gal-8 is a prognostic
marker for MM progression and disease.
3.1.1 Gal-8 in serum of MM patients
First, Gal-8 serum-levels of MM patients were measured by an ELISA (Figure 3.1).
The Gal-8 level in sera of MM patients was higher compared to that of age-matched
healthy donors (HD) (Figure 3.1 A). Only 22.2% (2/9) of HD in contrast to 45%
(19/42) of MM patients had Gal-8 protein present in their serum. HD did not display
elevated Gal-8 levels above 0.23ng/ml Gal-8, whereas Gal-8 levels in patients’ serum
had a maximum of 1.33ng/ml total protein content. It was not possible to perform
extended statistical analysis on the data since too many patients as well as HD do
not express Gal-8. This leads to a high variance within the expression data.
Subdivision of the patients’ sera with regards to secreted protein showed that MM
patients producing Bence-Jones (BJ) protein have the highest mean Gal-8 expres-
sion level compared to HD. The highest measured values were in patients with IgG
seroprotein (Figure 3.1 B).
3.1 Gal-8 expression in MM and correlation to the progression of the disease 46
HD MM 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
G
a
l-
8
 [n
g
/m
l]
A B
HD IgG IgA BJ
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
G
a
l-
8
 [n
g
/m
l]
Figure 3.1: Gal-8 serum levels in MM patients compared to healthy donors
Gal-8 serum levels were measured in sera of 42 MM patients and compared to sera of 9 HD. The mean
age of the MM patients was 55,95+/-8,35 years (39-70), the mean age of HD was 58.6+/-6.2 years (48-
68years) A: The mean Gal-8 serum level was higher in patients compared to HD. B: Subdivision of MM
sera according to types of secreted protein showed elevated levels of Gal-8 protein in all serotypes and the
highest in IgG. The graph shows mean Gal-8 concentration +/-SEM.
3.1.2 Gal-8 expression in the progression of MM
MM development is accompanied by many genetic changes from the pre-stage MGUS
which is defined by irregular serum protein in blood or urine. The mechanisms
and how and why MGUS proceeds to a fully established MM are unclear. Gene
expression data from BM biopsies of patients with MGUS, previously untreated MM
and healthy normal donors were analyzed focussing on Gal-8 expression. Microarray
analyses of gene expression profiles revealed that Gal-8 expression did not change
significantly during the disease progression (Figure 3.2), but some patients showed
elevated levels of Gal-8 transcription higher than the maximum gene expression in
HD. Although the mean mRNA expression level is comparable, the range was higher
in MM (min: 2.46; max: 8.74) than in HD (min: 5.37; max: 7.44).
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Figure 3.2: Gal-8 expression in MM patients compared to healthy donors
Microarray analyses of Gal-8 gene expression profiles in MGUS (n=22), MM stage I (n=59), stage II
(n=46) and stage III (n=226) were compared to HD (n=10). There was no significant change in the Gal-8
expression during the disease progression, but the range of expression was higher in MM patients than in
HD.
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3.1.3 Gal-8 expression is correlated to over-all survival in MM patients
Next, I tested the prognostic value of Gal-8 expression with regard to MM pro-
gression by Kaplan-Meier survival analysis. Patients were classified in Gal-8high and
Gal-8low using a median cut of the expression values (median=6.063+/-0.08). The
over all survival (OAS) analysis showed that Gal-8 expression negatively correlates
with survival of patients (Figure 3.3 A). The survival data was validated by two
independent cohorts treated within the total therapy 2 (TT2) [115] or the total
therapy 3 (TT3) [116] protocol (Figure 3.3 B, C).
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Figure 3.3: OAS of Gal-8 high vs. Gal-8 low patients
The prognostic value of Gal-8 expression for OAS was tested. Median cut was performed to distinguish
Gal-8high and Gal-8low expressing patients. A: OAS of the test cohort showed a longer survival for patients
with low Gal-8 expression (* p=0.0406). B: the data was validated on the TT2 dataset (* p=0.0435) and
C: on the TT3 dataset (** p=0.0108).
The correlation of Gal-8 expression with OAS could also be confirmed with regard
to the event-free survival (EFS) of the patients (Figure 3.4 A). Gal-8high patients
progress faster to the disease stage I than Gal-8low patients. The EFS data was also
validated by the TT2 and TT3 cohort (Figure 3.4 B, C).
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Figure 3.4: EFS of Gal-8 high vs. Gal-8 low patients
The prognostic value of Gal-8 expression for EFS was tested. Median cut was performed to distinguish Gal-
8high and Gal-8low expressing patients. A: EFS of the test cohort showed a slower progression to stage I for
patients with low Gal-8 expression (* p=0.047). B: the data was validated on the TT2 dataset (p=0.0873)
and C: on the TT3 dataset (* p=0.0149).
MM is characterized by many chromosomal aberrations. Main mutations found in
MM patients are gain of 1q21, the loss of 13q14 or the chromosomal translocation
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t4;14. Correlation analyses showed, that Gal-8 expression is significantly higher in
patients with a gain in 1q21 (Figure 3.5 A), a loss in 13q14 (Figure 3.5 B) or a
translocation in t4;14 (Figure 3.5 C).
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Figure 3.5: Gal-8 expression correlated to chromosomal aberrations
Gal-8 expression was plotted as log2 gene expression and correlated to A: 1q21 gene copy number B: 13q14
gene copy number and C: t4;14 translocation. All three chromosomal aberrations showed a significant up
regulation of Gal-8 expression.
As further chromosomal abnormalities I analyzed translocation t11;14 and 17p dele-
tion. These chromosomal aberrations did not show a significant change in Gal-8 gene
expression.
The patients’ data indicate that Gal-8 might play a role in MM progression. In order
to investigate the influence of Gal-8 on MM disease progression on the molecular
level, several in vitro angiogenesis and homing assays were performed analyzing the
role of Gal-8 in MM.
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3.2 Gal-8 expression in cell lines of MM and endothelial
origin
For in vitro studies on synthesis and expression of Gal-8 in MM, Gal-8 transcription
levels were measured in different cell lines of MM origin [117]. Microarray analysis
of these cell lines revealed that Gal-8 expression is very heterogenous among them
(Figure 3.6 A). This heterogeneity is also reflected in patients’ data on the Gal-
8 transcription level (Figure 3.6 B), from the 332 patients analyzed, the mRNA
transcription levels varied among them. This very heterogenous gene expression is
known for many proteins in MM [118, 119].
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Figure 3.6: Gal-8 expression in several MM cell lines and 332 MM patients
Microarray analyses showed, that Gal-8 expression is very heterogenous in several MM cell lines (A) as
well as in MM patients (B).
For further detailed analyses in this study, two different MM cell lines, the Gal-8
positive cell line MOLP-8 and the Gal-8 negative cell line LP-1, were chosen. Ad-
ditionally, the endothelial cell line HBMEC-60 and primary endothelial cells (HU-
VEC) were included in this study. A qRT-PCR was performed to study the Gal-8
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mRNA expression level of those cell lines (Figure 3.7 A). MOLP-8, as well as the
endothelial cells express Gal-8 in contrast to the MM cell line LP-1. To determine
if both isoforms (short and long linker) of Gal-8 are expressed, a PCR spanning the
linker region was performed using the same mRNA isolates. The PCR showed, that
both isoforms are expressed in MOLP-8 and the endothelial cells (Figure 3.7 B). In
contrast to EC, MOLP-8 expressed more Gal-8S than Gal-8L on the mRNA level.
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Figure 3.7: PCR analyses of Gal-8 expression in the different cell lines used in this study
A: Quantitative levels of Gal-8 expression were obtained using real-time PCR. MOLP-8 as well as both ECs
express Gal-8 whereas the MM cell line LP-1 is Gal-8 negative B: To detect the expression of the different
isoforms, PCR spanning the linker region was used. For the short-linker isoform a product with 950bp is
expected, for the long-linker isoform a product with 1150bp. Both isoforms are expressed by MOLP-8 and
the EC.
Protein levels of cells expressing Gal-8 were examined by Western blot analysis.
Since protein levels are very low, an IP was performed prior to the Western blot.
MOLP-8 as well as the ECs express Gal-8 protein (Figure 3.8 A). However, MOLP-8
expresses lower amounts of Gal-8L compared to Gal-8S, as it has also been seen on
the mRNA level. A quantitative ELISA revealed that the cells were able to secrete
Gal-8 into the supernatant (Figure 3.8 B), but it is not possible to define which
isoform since the amount of protein was under the detection limit of the Western
blot.
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Figure 3.8: Gal-8 protein levels in cell lysates and cell culture supernatants of MM and EC
A: Western blot against Gal-8 protein after an IP of whole cellular lysates. The MM cell line MOLP-
8 expressed Gal-8S stronger than Gal-8L. LP-1 was Gal-8 negative. HUVEC and HBMEC-60 express
both isoforms in comparable amounts. B: Anti-Gal-8 ELISA of conditioned supernatants. MOLP-8 as well
as both EC cells were able to release Gal-8 into cell culture supernatants. Representative data of three
independent experiments is shown for the IP, cumulative data of three independent experiments is shown
for the ELISA.
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3.3 Binding of lectins to cell lines of MM and endothelial
origin
Gal-8 is a lectin binding β-galactosides. The C-CRD prefers polyLacNac, blood group
A and B structures, whereas the N-CRD recognizes lactosaminyl structures, but also
sialylated and sulfated oligosaccarides [97]. It is noticeable that the N-CRD has in
general a higher affinity to carbohydrate binding partners than the C-CRD [97].
3.3.1 Binding of SNA, MAA and PNA to MM and EC
The lectins PNA, MAA and SNA were used for MOLP-8 and LP-1 staining in order
to compare the glycan structures important for Gal-8 binding expressed on the cell
surface. Both, α2,3 as well as α2,6 sialylated structures are present on both cell lines
as indicated by SNA and MAA binding. Stronger SNA staining indicates more α2,6
sialylated structures on both MM cell lines. PNA binds stronger to MOLP-8 than
to LP-1, indicating more terminal galactose-containing carbohydrates, in particular
those with a terminal Galβ1-3GalNac on MOLP-8 cells (Figure 3.9).
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Figure 3.9: Binding of SNA, MAA and PNA to MM
MM were incubated with 10µg/ml of the indicated biotinylated lectins and binding was measured via FACS
analyses. SNA, MAA and PNA were able to bind both MM cell lines. The median fluorescence intensity
(MFI) is indicated in each histogram.
The same FACS experiment was performed on EC. HBMEC-60 have less α2,3 than
α2,6 sialylated structures detectable on their surface. This is in contrast to HUVEC,
which bind MAA better than SNA, indicating more α2,3 sialylation. But in general,
HUVEC have less sialylated structures on their surface compared to HBMEC-60.
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PNA, is also able to bind both EC, but HUVEC stronger than HBMEC-60 (Figure
3.10).
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Figure 3.10: Binding of SNA, MAA and PNA to EC
EC were incubated with 10µg/ml of the indicated biotinylated lectins and binding was measured using
FACS analyses. SNA, MAA and PNA were able to bind both EC cell lines. The MFI is indicated in each
histogram.
3.3.2 Binding of different galectins to MM and EC
The ability of biotinylated Gal-1, -2, -3, -4, -8S and -9 to stain MM and EC cells
was compared by flow cytometry. Gal-1 and -2 are prototype, Gal-3 is chimeric and
Gal-4, -8S and -9 are tandem-repeat galectins. The median fluorescence intensity
(MFI) was measured to compare the binding of the different galectins (Figure 3.11).
Gal-1, -2, -3, -8S and -9 bound both EC. The strongest MFI was detected for Gal-8S
in both, HUVEC and HBMEC-60. Differential staining was only observed for Gal-3
which bound strongly to HBMEC-60, but much weaker to HUVEC. In general, the
affinity of the different galectins was weaker on MM. Gal-3 and Gal-8S were able
to attach to both MM cell lines, binding of Gal-1 and -2 was only slightly above
background fluorescence. Gal-4 was not able to recognize any cell line tested.
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Figure 3.11: Binding of several galectins to cells of MM and endothelial origin
Binding of 1µg of the indicated biotinylated galectin to the endothelial cells HUVEC or HBMEC-60 or
to the MM cell lines MOLP-8 and LP-1. EC as well as both MM cell lines bound strongest to Gal-3 and
Gal-8S. Binding of Gal-8S was stronger of EC then of MM.
Gal-8 and Gal-3 have been the strongest binders to both, MM and EC, among all
galectins tested in this study. As the influence of Gal-8 on MM and EC is the aim of
this study, further analysis have been performed using also the long-linker isoform
and the N-CRD of Gal-8.
3.3.3 Binding of Gal-8 to MM and EC
For the binding-analysis of both Gal-8 isoforms and the single N-terminal domain,
I performed dose response tests to define the optimal concentration. For this initial
experiment, HBMEC-60 and MOLP-8 were chosen. For further analysis, 200nM
Gal-8 were used as an optimum concentration for both isoforms as well as for the N-
terminal domain (Figure 3.12). The binding of the single C-terminal CRD could not
be measured, because the biotinylated C-CRD was not available. The production of
the single C-CRD is technically difficult and the low amount of protein I obtained
was used for thermophoresis experiments (see below section Gal-8 multimerization).
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Figure 3.12: Concentration curves Gal-8 binding
HBMEC-60 and MOLP-8 cells were incubated with increasing concentrations of biotinylated Gal-8S, Gal-
8L and Gal-8N in order to determine the optimal protein concentration for binding analyses. The binding
was concentration dependent and an optimum for both cell lines and all Gal-8 isoforms was around 200nM.
The binding of both Gal-8 isoforms as well as the single N-terminal domain (Gal-
8N) was tested by flow cytometry. For this purpose, 200nM of Gal-8S, Gal-8L or the
biotinylated Gal-8 N-terminal CRD were incubated with either LP-1 or MOLP-8
cells. Both isoforms were able to recognize both MM cell lines (Figure 3.13). The N-
terminal domain alone bound only LP-1, the staining of MOLP-8 was hardly above
the fluorescence intensity of the negative control. The binding could be inhibited
by addition of 100mM lactose, indicating that the binding of Gal-8 to MM cells is
dependent on the cell surface expressed glycan structures. It is noticeable that Gal-8
bound LP-1 generally stronger than MOLP-8.
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Figure 3.13: Binding of Gal-8 to MM cells
Binding of both Gal-8 isoforms and the N-terminal domain was investigated by incubation of the cells with
200nM of the respective recombinant Gal-8 protein followed by cytofluorographical analysis. Representa-
tive analyses of three independent experiments are shown. The MFI of bound Gal-8 is indicated in each
histogram.
Also, Gal-8 binding efficiency to EC was measured showing that the two Gal-8
isoforms as well as the N-terminal domain were ably to bind both EC types (Figure
3.14). The binding was stronger to HUVEC than to HBMEC-60 and inhibited by
addition of 100mM lactose indicating that the interaction is mediated by protein-
glycan recognition and not by protein-protein interactions as already observed with
MM cells.
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Figure 3.14: Binding of Gal-8 to EC
Binding of both Gal-8 isoforms and the N-terminal domain was investigated by incubation of the cells with
200nM of the respective protein followed by cytofluorographical analysis. Representative analyses of three
independent experiments are shown. The MFI of bound Gal-8 is indicated in each histogram.
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3.3.4 Gal-8 binding after VCN-treatment
VCN-treatment reduces terminal N-acetylneuraminic acids linked in α2,3-, α2,6-, or
α2,8 fashion. As the Gal-8 N-terminal CRD prefers α2,3 sialylated structures for
binding, VCN treatment on intact cells should reduce Gal-8N binding.
The effectiveness of VCN-treatment was exemplarily checked on MOLP-8 cells
by SNA, MAA and PNA staining (Figure 3.15).
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Figure 3.15: VCN treatment of MOLP-8
Cells were treated with VCN for 1h at 37°C and SNA, MAA and PNA binding was measured subsequently.
The MFI of bound lectin is indicated in each histogram.
As expected, SNA and MAA binding is decreased after VCN-treatment, accord-
ingly PNA staining increases. Terminal Galβ1-3GalNac are often masked by sia-
lylation preventing PNA binding. It was remarkable that SNA-binding was only
slightly altered indicating only a slight decrease of α2,6-sialylation, whereas MAA-
binding was almost completely abolished showing an almost complete removal of
α2,3-sialylation by VCN. Another explanation for this phenomenon is the possibil-
ity that α2,6 sialylated surface structures are not sterically available for the enzyme.
In order to determine whether Gal-8 binding is dependent on the sialylation of
MM or EC, a Gal-8 staining was performed after VCN-treatment of the different
cell lines (Table 3.1).
MOLP-8 LP-1 HUVEC HBMEC-60
UT VCN UT VCN UT VCN UT VCN
Gal-8S 15,877* 34,141 28,158 18,934 56,130 32,217 32,957 24,050
Gal-8L 17,601 20,677 32,957 17,779 63,203 46,683 33,628 21,473
bGal-8N 260 225 149 126 467 228 511 153
Table 3.1: Impact of VCN treatment on Gal-8 binding
*Binding of Gal-8 is indicated by MFI values. UT=untreated, VCN=treated with VCN for 1h at 37°C
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VCN-treatment reduces Gal-8S and Gal-8L binding on the cell surface of EC,
pointing out the affinity of both isoforms to α2,3 sialylated structures, as α2,6 sialy-
lation can not be recognized by Gal-8N [95]. On the MM side, LP-1 and MOLP-8
differed after VCN-treatment. Desialylation reduced binding of Gal-8 to LP-1, but
increased binding on MOLP-8 indicating a difference in surface glycosylation of the
two MM cell lines.
The MFI for Gal-8N binding was remarkably lower than the MFI for the full-
length protein. This is possibly due to the biotinylation of the N-CRD leading to
a lower affinity of the protein. Unbiotinylated Gal-8N can not be detected by the
monoclonal antibody, as the full length protein, since the antibody binds an epitope
in the C-CRD. Binding of the N-terminal domain is not altered after desialylation
on the MM cell lines but decreases on both EC types. This points to the possibility,
that EC are preferred targets for the N-CRD and MM cells might be preferably
bound by the C-CRD.
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3.4 Influence of Gal-8 on (tumor-) angiogenesis
The formation of new blood vessels is a tightly regulated process involving several
signaling pathways and cell-cell interactions. In MM, tumor angiogenesis is a crucial
step for the development and progression of the disease. MM cells are able to promote
angiogenesis, a higher microvessel density in the BM of patients is a marker for faster
progression [24]. Previously, Gal-8 has been described to be a pro-angiogenic factor
[101]. I performed several in vitro angiogenesis assays in order to examine in more
details whether Gal-8 induces angiogenesis.
3.4.1 Influence of Gal-8 on proliferation of EC and fibroblasts
The endothelium is usually quiescent after the formation of a vasculature. After
pro-angiogenic stimuli, such as hypoxia, EC start to proliferate to form new blood
vessels [14]. The influence of recombinant Gal-8 on EC proliferation was measured
using a [3H]-tymidine-incorporation assay. Neither Gal-8S nor Gal-8L had significant
influence on the proliferation of HUVEC, solely the N-terminal domain at 0.5µM had
negative effects on the proliferation (Figure 3.16 A). For HBMEC-60, both isoforms
had a slightly positive effect on proliferation at 0.5µM. The N-terminal domain had,
as seen before in HUVEC, a negative effect on proliferation (Figure 3.16 B).
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Figure 3.16: Influence of Gal-8 on proliferation of EC
EC were stimulated for 24h with the indicated concentration and isoform of Gal-8 prior to the addition
of [3H]-thymidine for 8h. Graphs show the proliferation of HUVEC (A) or HBMEC-60 (B) compared to
medium control. 0.5µM Gal-8S and -8L have pro-proliferative effects on HBMEC-60, whereas 0.5µM of
the N-terminal domain has negative effects on the proliferation of both EC. Cumulative data of three
independent experiments are shown.
Besides EC, fibroblasts were used as feeder cells in the tube formation assay (see
below) and ECM-derived components play a critical role in EC lumen formation
[120]. Addition of Gal-8 did not significantly influence the proliferation of fibroblasts.
(Figure 3.17).
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Figure 3.17: Influence of Gal-8 on proliferation of fibroblasts
Fibroblasts were treated as described above (Figure 3.16). The graph shows the proliferation of fibroblasts
compared to medium control. No effects of Gal-8 on fibroblasts was observed. Cumulative data of three
independent experiments is shown.
For further angiogenesis-experiments, HUVEC were used. Although HBMEC-60
cells were originally isolated from the bone marrow and are derived from a typi-
cal microenvironment of MM, they can not be used for the tube formation assay.
For reasons not clearly understood the retrovirally immortalized HBMEC-60 have
lost the capability to form tubes in vitro. HUVEC are a primary cell line and are
therefore more suitable for angiogenesis assays.
3.4.2 Influence of Gal-8 on EC migration
Another mechanism influencing the formation of new blood vessels is the ability
of EC to migrate. In the course of sprouting angiogenesis, EC line up and follow
a tip cell to built a new blood vessel [14]. The influence of recombinant Gal-8 on
EC migration was analyzed using a gap closure assay. For this purpose, HUVEC
were seeded in IBIDI cell culture inserts and grown until confluency. The inserts
were removed leaving a gap in the confluent HUVEC layer and Gal-8S or Gal-8L
were added in different concentrations (0.1µM or 0.5µM) to the medium. Photos
were taken every 20min for 10 hours and the percentage of uncovered area was
calculated. Neither Gal-8S nor Gal-8L had a significant influence on the migratory
potential of HUVEC (Figure 3.18).
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Figure 3.18: Influence of Gal-8 on wound healing
HUVEC were seeded in IBIDI cell culture inserts and grown for 24h and cell migration after addition of
indicated amounts of Gal-8 was monitored using a Zeiss Cell Observer. The percentage of uncovered area,
dependent on the time after removal of the insert, was measured using the ImageJ program. Addition
of Gal-8 to the culture medium did not affect HUVEC migration. Cumulative data of three independent
experiments is shown, mean+/-SEM is depicted.
3.4.3 Influence of Gal-8 on in vitro tube formation
Former studies on the influence of Gal-8 on angiogenesis used the matrigel-assay
which is rather a network-formation assay than a 3D angiogenesis assay in which tube
formation can be observed [101]. Therefore, a tube formation assay was performed
which consists of a co-culture based on a fibroblast-feeder layer and ECs seeded on
top. Addition of VEGF-165 to the co-culture was used as a positive control for tube
formation. Tubes were visualized by CD31 staining (Figure 3.19).
20ng/ml VEGF-165medium
Figure 3.19: Tube formation assay
EC were cultured on top of a fibroblast feeder layer and tube formation was induced with 20ng/ml VEGF-
165. Tubes were visualized by staining of CD31. VEGF-165 was able to induce tube formation on the
HUVEC. The figure shows representative pictures of three independent experiments.
The angiogenic potential of Gal-8 was tested by the addition of the lectin to the co-
culture. Tube formation was quantified by counting the number of tubes. Incubation
of the fibroblast-EC co-culture with 0.1µM Gal-8 in addition to VEGF-165 for three
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or seven days did not lead to any significant increase in tube formation (Figure 3.20
A, B).
Using 0.5µM Gal-8 without parallel application of VEGF-165, a slight increase in
tube formation was observed after 3 days of the co-culture for Gal-8S. But this
effect was lost again after seven days (Figure 3.20 C, D). Gal-8 in combination with
VEGF-165 did not lead to any positive effect on tube formation.
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Figure 3.20: Tube formation assay
Fibroblast were seeded and grown till confluency prior to the addition of endothelial cells. No VEGF-165
(red bars), 2.5ng/ml VEGF-165 (blue bars) or 10ng/ml VEGF-165 (yellow bars) were applied in parallel
with 0.1µM (A, B) or 0.5µM (C, D) of the indicated Gal-8 isoform. The cells were cultured for either 3 days
(A, C) or 7 days (B, D). Tubes were visualized by CD31 staining, the tube formation was quantified by
counting the number of tubes per picture using the software Angiosys. A slight increase in tube formation
was seen after three days using 0.5µM Gal-8S without parallel application of VEGF-165. Addition of lower
concentrations of Gal-8S or the other isoforms did not increase tube formation. Cumulative data of three
independent experiments is shown.
Summarizing all results of the angiogenesis experiments, no pro-or anti-angiogenic
effect was observed for Gal-8. There was only a slight effect of Gal-8S in high con-
centration on the tube formation potential of HUVEC, but there was no clear pro-
angiogenic effect detectable.
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3.5 Gal-8 in MM biology
Besides tumor-angiogenesis, MM proliferation and homing of the tumor cells into
the bone marrow play crucial roles in the development of the disease. Since Gal-8 has
been shown to influence adhesion processes by binding to integrins in other cell lines
[75, 76, 77, 78], the effect of Gal-8 on MM proliferation and homing was examined.
3.5.1 Influence of Gal-8 on proliferation of MM
Massive proliferation of MM cells in the BM leads to a rapid progression of the
disease. A [3H]-thymidine proliferation assay was performed investigating the influ-
ence of Gal-8 on MM proliferation. MM cells were seeded and treated with 0.1µM
or 0.5µM of the indicated Gal-8 for 24h. For both cell lines tested, Gal-8N at high
concentrations had a negative effect on proliferation (Figure 3.21). For LP-1, Gal-8S
had a slightly positive effect on proliferation (Figure 3.21 B).
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Figure 3.21: Influence of Gal-8 on proliferation of MM
MM were stimulated for 24h with the indicated concentration and isoform of Gal-8 prior to the addition
of [3H]-thymidine for 8h. Graphs show the proliferation of MOLP-8 (A) or LP-1 (B) compared to medium
control. Gal-8S had a slightly positive effect on the proliferation of LP-1. 0.5µM Gal-8N had a negative
effect on the proliferation of both MM cell lines. Cumulative data of three representative experiments are
shown.
Overall, it seems that Gal-8 has only minor influence on the proliferation rates of
MM cells in vitro.
3.5.2 Gal-8 in MM homing
Homing of the MM cells to EC in the BM is an initial step for invasion of MM
into the bone. The impact of Gal-8 on homing of MM to EC was investigated next.
In literature, Gal-8 has been described to be able to influence cell-cell as well as
cell-ECM adhesion processes in several biological systems [75, 76, 77, 78].
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3.5.2.1 Static adhesion
In order to investigate if Gal-8 is a pro-adhesive effector on MM adhesion to EC,
HUVEC were seeded and grown until confluency prior to the addition of calcein-
green stained MM cells. MM cells were allowed to adhere for 30min at 37°C, then
non-adherent cells were gently washed away and adherent cells were counted. Ad-
dition of 0.1µM Gal-8 led to a stronger adhesion of both MM cell lines to the EC.
Gal-8L had a stronger effect compared to Gal-8S, whereas the N-terminal domain
alone did not influence adhesion. The addition of 100mM lactose led to an inhibition
of the pro-adhesive effect of Gal-8 (Figure 3.22). This indicates that the positive ef-
fect on adhesion is mediated by galectin-glycan interactions. Additionally it shows
that the N-terminal domain alone did not have such positive effect indicating that
either both domains are necessary for the pro-adhesive effect or the single C-CRD.
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Figure 3.22: Static adhesion of MM to EC
MM cells were stained with calcein-green and adhesion of the cells to HUVEC was measured. MOLP-8
(A) as well as LP-1 (B) were able to adhere stronger in the presence of recombinant Gal-8. Gal-8L had a
significantly stronger effect than Gal-8S in LP-1. The N-terminal domain had no pro-adhesive effect. The
adhesion was inhibited in the presence of 100mM lactose (light blue bars). The graph shows cumulative
data of three independent experiments and depicts mean +/- SEM
Since the adhesion assay showed that Gal-8S and Gal-8L had distinct effects on the
adhesion, different mutants, lacking parts of the linker region, were used for further
experiments. Figure 3.23 displays the deleted regions. The deletion of amino acids
led to linker sizes ranging in between the long and the short linker isoform. In the
following experiment the questions which parts of the linker lead to the stronger
effect on adhesion, were addressed.
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GFSFSSDLQSTQASSLELTEISRENVPKSGTPQLPSNRGGDISKIAPRTVYTKSKDSTVNHTLTCTKIPPMNYVSK
GFSFSSDLQSTQASSLELTEISRENVPKSGTPQL
GFSFSSDLQSTQASSLELTEISRENVPKSGTPQLPSNRGGDISKIAPR
GFSFSSDLQSTQASSLELTEISRENVPKSGTPQLPSNRGGDISKIAPRTVYTKSKDSTVNHT
GFSFSSDLQSTQASSLELTEISRENVPKSGTPQL                                                                        LTCTKIPPMNYVSK
GFSFSSDLQSTQASSLELTEISRENVPKSGTPQL                                   TVYTKSKDSTVNHTLTCTKIPPMNYVSK
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Figure 3.23: Mutation of the Gal-8 linker region
Comparison of the linker region amino-acid sequence of Gal-8S, Gal-8L and mutants with a partly deleted
linker region. The deletions are indicated as a black lines, number of amino-acids in the linker region are
displayed.
All Gal-8 linker mutants,with or without the addition of 100mM lactose, did not
have any significant effect on the adhesion of MM to EC (Figure 3.24). Although not
significant, Mut2 and MutA slightly increased the adhesion of MOLP-8 to HUVEC.
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Figure 3.24: Static adhesion - Gal-8 linker mutants
MM cells were stained with calcein-green and adhesion of the cells to HUVEC was measured. Gal-8 mutants
with partly deletions of the linker region did not change the adhesion of MOLP-8 (A) or LP-1 (B) to the
EC. Only Mut2 and MutA were able to slightly increase the adhesion of MOLP-8 to HUVEC. Additionally,
addition of 100mM lactose did not affect binding. The graph shows cumulative data of three independent
experiments.
It seems that all mutant isoforms of Gal-8 are non-functional in terms of adhesion
of MM to EC. This is possibly due to the deletions of essential amino acids in the
linker region. This might have caused a general unstable and therefore non-functional
protein.
Since it was shown that Gal-8 has an effect on adhesion of MM to EC, more ex-
periments were performed to go further into details. The following paragraph will
focus on the question if the pro-adhesive effect of Gal-8 is also present under shear
stress conditions. Additionally, the impact of an inflammatory environment on the
adhesion was examined.
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3.5.2.2 Changes in the expression of surface molecules after TNF-α
stimulation in MM
Stimulation with TNF-αmimics an inflammatory environment. The expression of the
glycoproteins neuronal cell adhesion molecule (NCAM; CD56) and MAC-inhibitory
protein (MAC-IP; CD59), cyclic ADP ribose hydrolase (CD38), the MM cell marker
syndecan I (CD138) as well as HLA class 1(W6/32) were measured after stimulation
of the MM cells with 10ng/ml TNF-α for 24h (Figure 3.25). Unexpectedly, HLA-
surface expression was decreased on LP-1 after TNF-α stimulation. This effect was
seen in two independent measurements and could be due to tumor-escape mech-
anisms. Major difference between LP-1 and MOLP-8 is the expression of NCAM
which is present on the surface of MOLP-8, but not or only to a small amount on
LP-1. All other molecules tested were expressed on both cell lines and not strongly
altered by TNF-α treatment.
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Figure 3.25: Expression of MM surface markers after TNF-α stimulation
MM cells were stimulated for 24h with 10ng/ml TNF-α. Expression of indicated surface markers was
detected by FACS analyses.
It seems that surface expression of the adhesion molecules tested are not strongly
activated in the presence of TNF-α in both MM cell lines.
3.5.2.3 Changes in the expression of adhesion molecules in EC
Vascular shear stress is an important factor for the homeostasis in the circulation.
Since vascular EC are constantly exposed to shear stress and respond to it, this
must be also considered by the investigation of homing processes. One example that
shows the importance of shear stress is that selectin-mediated rolling depends on
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shear stress, since the adhesion stops under static conditions [42]. It has also been
shown that shear stress regulates the expression of certain adhesion molecules e.g.
the expression of VCAM-1 decreases remarkably in cells exposed to shear stress in
vitro [42, 121]. Microarray analyses revealed that around 3% of 5600 genes tested
respond to shear stress stimulation [122]. It is also noticeable, that cells cultured
under shear stress conditions change their morphology, they become more streched,
line up and their actin skeleton is remodeled [121, 123]. Those responses to shear
stress indicate that ECs are able to sense shear stress specifically, but the mechanisms
of mechanotransduction and are not fully understood yet [121].
In order to obtain a comprehensive view on the influence of shear stress or inflamma-
tory stimulation on the expression profile of EC whole genome analyses of HUVECs
treated with either 10 ng/ml TNF-α for 24h, 10 dyn/cm2 shear stress for 24h or
both were performed. 188 genes that are important for adhesion processes were ex-
tracted from the dataset using a gene list according to the KEGG-pathway 4514
(http://www.genome.jp/dbget-bin/www_bget?pathway:map04514). The resulting
heatmap shows, that HUVEC change their expression profile of adhesion molecules
upon stimulation with shear stress, as well as after stimulation with TNF-α or both
(Figure 3.26). All four datasets show different clusters of genes expressed resulting
in a selective expression pattern for each group.
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Figure 3.26: Heatmap of adhesion molecules under inflammatory stimulation or shear stress
HUVEC were treated with 10ng/ml TNF-α for 24h, 10dyn/cm2shear stress or both prior to the mRNA-
analyses. Whole genome analysis was performed on a Illumina HT12 Chip and 188 genes from the KEGG
pathway 4514 were selected for the heatmap analysis. Red color indicates upregulated genes, green color
indicates downregulated genes. The x-axis indicates the treatment of the cells, the y-axis shows the hi-
erarchical clustering of the selected genes. Different gene-expression patterns were seen comparing the
four different treatments. Shear stress as well as stimulation with TNF-α altered the expression profile of
HUVEC remarkably.
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The data obtained from the heatmap analysis was verified by qRT-PCR on selected
genes (Figure 3.27). The expression of ICAM-1 (CD54) was slightly upregulated by
shear stress, but the expression of E-selectin (CD62E) was suppressed. The stimu-
lation with TNF-α for 24h in addition to shear stress led to a massive increase of
ICAM-1 and E-selectin expression on the mRNA level. The expression of PECAM-1
(CD31) and VE-cadherin (CD144) was not altered.
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Figure 3.27: mRNA expression of surface markers after 24h shear stress +/- TNF-α
HUVEC were seeded and grown in a µSlide for 24h at 10dyn/cm2. Cells were additionally stimulated with
10ng/ml TNF-α, as indicated. Shear stress suppresses the expression of the adhesion molecule CD62E,
stimulation with TNF-α strongly increases the expression of CD62E and CD54. The expression of CD31
and CD144 are not altered by shear stress or TNF-α stimulation. Graph shows representative data of three
independent experiments.
FACS analyses were performed in order to check the regulation of the selected genes
on the cell surface. It is not possible to perform this experiment on cells stimu-
lated with shear stress, due to limited numbers of cells to recover from the shear
stress system. However, the change of expression of surface markers was measured
after TNF-α stimulation under static conditions by FACS analysis (Figure 3.28).
According to the qRT-PCR data, the expression of the adhesion molecules CD54
and CD62E is increased on HUVEC after stimulation with TNF-α. The positive
control HLA class 1 is also upregulated after TNF-α stimulation. The expression of
CD144 and CD31 was not changed. HUVEC and HBMEC-60 are comparable in the
expression of the tested surface molecules, except for CD62E, which seemed not to
be expressed on HBMEC-60, even after stimulation with TNF-α. This has also been
described before in our group by Willhauck-Fleckenstein et al. [124].
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Figure 3.28: Expression of EC surface markers after TNF-α stimulation
EC were stimulated for 24h with 10ng/ml TNF-α. Expression of indicated surface markers was detected by
FACS analyses. The expression of CD31 and CD144 remains stable, as has been shown before by qRT-PCR
analysis. CD54 and CD62E expression is increased after inflammatory stimulation, as expected, as well as
the positive control W6/32.
In summary, it was shown that due to inflammatory or shear stress conditions, HU-
VEC change their expression of characteristic cell surface molecules. These changes
in the expression of adhesion molecules need to be considered for adhesion experi-
ments, since both, shear stress and TNF-α can alter the expression of them. There-
fore, the results of the static adhesion experiments were confirmed in an adhesion
assay under shear stress conditions and by the combination of shear stress and
TNF-α stimulation during the experiments.
3.5.2.4 Homing of MM to EC in shear stress conditions
Adhesion experiments were performed mimicking a blood vessel. The experiment was
performed as shown in Figure 3.29. HUVEC were seeded and grown for 24h at 10
dyn/cm2 with or without the addition of 10ng/ml TNF-α. After the pre-stimulation,
calcein-green stained MM cells were first perfused at lower shear stress (1 dyn/cm2)
for 30 minutes to mimic shear stress in small vessels. Afterwards, shear stress was
raised to 5 dyn/cm2 to check if the cells adhere firmly or were just loosely attached.
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Figure 3.29: Schematic overview of shear stress experiments
The figure shows how shear stress experiments were performed in general. HUVEC were seeded and pre-
cultivated under shear stress for 24h prior to an experiment. During the experiment, microscopic pictures
using a Zeiss Cell Observer.Z1 (objective: 5× / 0.16 EC Plan-NEO Ph1 DIC0) were taken and calcein-green
stained cells were counted for quantification.
Initial shear-stress experiments were performed with non-inflammatory HUVEC.
Although only a few cells were able to adhere, the Gal-8 expressing MM cell line
MOLP-8 adhered stronger to HUVEC under shear stress than the Gal-8 negative
cell line LP-1 (Figure 3.30).
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Figure 3.30: Adhesion of MM to EC under shear stress
Adhesion of MOLP-8 or LP-1 MM cells to HUVEC during 30 min of 1dyn/cm2followed by shear stress
of 5dyn/cm2for 10 min. Adherent cells were counted every 30 sec during shear stress (A). The number
of adherent cells/position after 30 min was used for statistical analyses (B). The Gal-8 positive cell line
MOLP-8 was able to adhere stronger than the Gal-8 negative cell line LP-1. But only a few cells were able
to adhere in general. The graph shows cumulative data of three independent experiments.
The expression of adhesion molecules on the surface of HUVEC was induced by
pre-stimulation with TNF-α before the adhesion experiments. After pre-stimulation
with TNF-α, approximately 100-fold more cells were able to adhere. In this case, the
Gal-8 negative cell line LP-1 showed stronger binding compared to MOLP-8 (Figure
3.31).
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Figure 3.31: Adhesion of MM to EC under shear stress
HUVEC were pre-stimulated with 10 ng/ml TNF-α before the perfusion with MM cells as described above.
Adherent cells were counted every 30 sec during shear stress (A). The number of adherent cells/position
after 30 minutes was used for statistical analyses (B). Under inflammatory stimulation, about 100-fold
more MM cells were able to adhere. LP-1 adhered stronger than MOLP-8. Graph shows cumulative data
of three independent experiments.
The influence of recombinant Gal-8 on the adhesion under shear stress conditions
was measured by the addition of 0.1µM Gal-8S or Gal-8L to the perfusion medium.
After 30 minutes of perfusion at 1 dyn/cm2, cells were able to adhere stronger if
Gal-8 was present in the medium (Figure 3.32). For both, LP-1 and MOLP-8, the
adhesion was significantly stronger if Gal-8L was present compared to Gal-8S. For
Gal-8S the adhesion was enhanced approximately 15-fold, for Gal-8L 40 to 60-fold.
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Figure 3.32: Influence of recombinant Gal-8 on adhesion
Adhesion of MOLP-8 (A, B) or LP-1 (C, D) MM cells to HUVEC during 30 min of 1 dyn/cm2 followed
by shear stress of 5 dyn/cm2 for 10 min. If indicated, 0.1µM Gal-8S or Gal-8L was added to the perfusion
medium. Adherent cells were counted every 30 sec during shear stress (A, C). The number of adherent
cells/position after 30 minutes was used for statistical analyses (B, D). The addition of Gal-8S as well as Gal-
8L increased the number of adherent MM cells significantly in both cell lines. Gal-8L increased the adhesion
significantly stronger then Gal-8S. Graph shows cumulative data of three independent experiments.
Since it was shown before that pre-stimulation with TNF-α influences the expression
of cell surface molecules and could thereby influence the adhesion of MM to EC too,
HUVEC were pre-treated with 10ng/ml TNF-α prior to the adhesion experiment.
As seen before, more MM cells were able to adhere to the HUVEC layer after
inflammatory stimulation. Addition of recombinant Gal-8 even increased the already
strong binding of MM to EC, but under these conditions there was no significant
difference between Gal-8S and Gal-8L (Figure 3.33).
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Figure 3.33: Influence of recombinant Gal-8 on adhesion to TNF-α stimulated HUVEC
HUVEC were pre-stimulated with 10 ng/ml TNF-α before the perfusion with MM cells (MOLP-8 A, B;
LP-1 C, D) as described above. If indicated, 0.1µM Gal-8S or Gal-8L was added to the perfusion medium.
Adherent cells were counted every 30 sec during shear stress (A, C). The number of adherent cells/position
after 30 min was used for statistical analyses (B, D). Gal-8S as well as Gal-8L were able to increase the
adhesion of MM to EC also after pre-stimulation with TNF-α. But there was no significant difference
between Gal-8S and Gal-8L. Graph shows cumulative data of three independent experiments.
The role of Gal-8 secreted by MM on the MM adhesion to EC was assessed using
conditioned supernatants of MOLP-8 cells. For this purpose, the cells were cultured
for 72h in serum-free AIM medium, which was then concentrated 20-fold. The con-
centrated medium was split into two parts and half of the supernatant was Gal-8
depleted prior to the shear stress experiment. The depletion was checked using a
Gal-8 specific ELISA (Figure 3.34 A). The conditioned supernatant and the Gal-
8 depleted supernatant were added to the perfusion medium and the adhesion of
MOLP-8 cells to HUVEC under shear stress was measured (Figure 3.34 B, C). After
30 minutes, a significant difference in adherent cells comparing Gal-8 conditioned
against Gal-8 depleted supernatant was detected (Figure 3.34 C).
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Figure 3.34: Shear stress using MOLP-8 conditioned supernatants
HUVEC were grown and perfused with MM cells as described above. Half of MOLP-8 conditioned super-
natant was Gal-8 depleted. Depletion was measured using a Gal-8 specific ELISA (A). The supernatant
was added to the perfusion medium. Adherent cells were counted every 30 sec during shear stress (B).
The number of adherent cells/position after 30 min was used for statistical analyses (C). The depletion of
Gal-8 in the conditioned supernatant lead to a significantly decrease in adherent MM cells. Graph shows
cumulative data of three independent experiments.
In conclusion, it was shown that Gal-8 has an effect on the adhesion of MM to EC
in static as well as in shear stress conditions. Gal-8L has a stronger pro-adhesive
effect in both systems than Gal-8S indicating that the two isoforms of Gal-8 differ
in their biological activity.
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3.6 Gal-8 multimerization
Seeing differences between the long- and short-linker isoform of Gal-8 in biological
assays, the question arises concerning the molecular background of this differential
behavior. Multimerization or galectin-glycan lattice formation is a process often
described for different galectins [58, 125, 126]. But there is only little experimental
evidence proving that these processes occur [60]. For Gal-8 it has been shown that
it can form dimers using chemical crosslinking [98]. For two Gal-1 CRDs connected
by artificial linkers homodi - and multimerization was shown, but this has never
been shown for tandem-repeat galectins [60]. Using SDS-PAGE analysis, static light
scattering and thermophoresis measurements it was investigated if differences in the
ability to form dimers or multimers occur in the two isoforms.
3.6.1 Non-reducing SDS-Gels
Gal-8 has been show to run as a dimer in SDS-PAGE after chemical crosslinking
[98], but it was not shown if this dimerization is also present without chemical mod-
ification. Recombinant Gal-8 was loaded on MOPS/SDS gels using non-reducing
loading buffer without the prior addition of a crosslinker. For the short-linker iso-
form, a band was observed at 36kDa. After longer exposure, a second signal appeared
at approximately 75kDa (Figure 3.35). For the long linker isoform 3 bands appeared,
a monomer at around 40kDa, a dimer at approximately 80kDa and a third band at
about 120kDa, representing most likely a trimer. The ratios of multimer to dimer
to monomer Gal-8L were 1:4.4:8.6. The ratios were investigated by calculating the
pixel density using the ImageJ software.
40kDa
250kDa
140kDa
100kDa
70kDa
50kDa
Gal-8S Gal-8L Gal-8S Gal-8L
short exposure long exposure
Figure 3.35: Non-reducing SDS-Gels of Gal-8S and Gal-8L
2µg of the indicated recombinant protein were loaded per lane of a 4%-12% MOPS/SDS precast gel. For
Gal-8S a monomer (36kDa) and a dimer (72kDa) band were observed, for Gal-8L a monomer (40kDa),
dimer (80kDa) and trimer (120kDa) were seen.
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In order to investigate if the dimer-or multimerization is forced by either the single
N-or C-terminal CRD, both domains were loaded on a gel as described above. Both
showed the formation of a dimer (Figure 3.36), using longer exposure times did not
show any tri- or multimers (data not shown). The ratio of dimers to monomer was
1:3.7 for Gal-8C and 1:7.4 for Gal-8N.
38kDa
52kDa
Gal-8C Gal-8N
31kDa
24kDa
19kDa
Figure 3.36: Non-reducing SDS-Gels of Gal-8N and Gal-8C
2µg of the indicated recombinant protein were loaded per lane on a 4%-12% MOPS/SDS precast gel. For
Gal-8C a monomer (17kDa) and a dimer (34kDa) band was observed. The same was shown for for Gal-8N,
a monomer (18kDa), dimer (36kDa) was visible.
It seems that more Gal-8C dimer is present than Gal-8N dimer, but this is due
to a general higher protein content for Gal-8C in the gel. Although the protein-
concentration of the suspension was determined before loading on the gel, it seems
that more Gal-8C was loaded than Gal-8N. The pixel intensity for both bands is
higher for Gal-8C (221.470) than for Gal-8N (207.603) indicating more total Gal-8C
protein. A possibility is that Gal-8N is more degraded than Gal-8C and that the
degradation products ran out the gel and are not visible anymore.
3.6.2 Static light scattering
SDS-PAGE separation indicated that Gal-8S and Gal-8L differ in their ability to di
- or multimerize in solution. Using a second method, static light scattering (SLS)
analysis (performed by Dr. Vladimir Rybin, EBML, Heidelberg), the presence of
dimers in both, Gal-8S and Gal-8L could be confirmed by the appearance of two
peaks (Figure 3.37). The ratio of dimer to monomer was 1:50 for Gal-8S and 2:3 for
Gal-8L. The calculated size for the monomers was 33kDa for Gal-8L and 35kDa for
Gal-8S, the size of the dimers was calculated with 67kDa for Gal-8L and 68kDa for
Gal-8S.
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Figure 3.37: Static light scattering of Gal-8S and Gal-8L
For static light scattering, proteins were loaded on a Superdex 200 column and elution of the protein was
detected by the refractive index (RI) at defined elution volumes. The RI signal is depicted on the y-axis,
the elution volume on the x-axis. Both, Gal-8S as well as Gal-8L have peaks for monomers and dimers
(indicated). But the ratio of dimers to monomers differs in both isoforms. For Gal-8S the ratio is 1:50 (A),
for Gal-8L 2:3 (B). The measurement was performed by Dr. Vladimir Rybin(EBML, Heidelberg).
The fact that Gal-8S has a higher calculated molecular weight than Gal-8L might
be due to differences in the protein folding influencing the migration of the protein
through the column. But the clear difference in the ration of monomer to dimer in
Gal-8S an Gal-8L indicates, that Gal-8L is more capable to build dimers in
solution.
3.6.3 Thermophoresis
Since differences between Gal-8S and Gal-8L in the formation of dimers or trimers
were seen in the SDS gels and SLS analysis, thermophoresis was used to calculate
binding coefficients of the self-interaction. Thermophoresis is a process that describes
the movement of a molecule along a temperature gradient. By fluorescence labeling
of one interaction partner, the movement can be tracked. If two molecules interact
with each other, a concentration dependent change in the movement is observed
(e.g. gets slower or faster) and this can be measured using the label of one of the
interaction partners (Figure 3.38) [127].
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Figure 3.38: Schematic overview of thermophoresis
A: For MST measurements, serially diluted samples are filled into capillaries. A punctual temperature
gradient is created by a IR-laser, the movement of molecules is detected using a fluorescence detector. B:
By turing the laser on, the molecules move out the temperature gradient which is detected by a drop of
the fluorescence (temperature jump) leading to a steady state situation after about 20 sec. After turning
the laser off, the molecules move back. This is detected by an increasing fluorescence signal. If molecules
interact with each other, the movement changes. The figure was taken from Jerabek-Willemsen et al. [127].
For the analysis of Gal-8 self-interactions, the protein was fluorescently labeled and
incubated with unlabeled protein in increasing concentrations of the same isoform.
A first change in the movement was seen for Gal-8S, Gal-8L and the N-terminal
domain very early during thermophoresis, at the initial temperature jump (Figure
3.39). This change shows probably the formation of a dimer and was present at
very low nano-molar concentrations (table 3.2). Gal-8L was about 5-fold stronger
in dimerization comparing the obtained EC50 values. A second, very weak event
occurred later during the thermophoresis for Gal-8L and Gal-8C (Figure 3.39). This
is seen by a change in the direction of the amplitude. The second event might be the
formation of a trimer for Gal-8L and the formation of a dimer for the C-terminal
domain. The obtained EC50 values were much higher as at the early event (table
3.2).
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Figure 3.39: Thermophoresis of Gal-8 isoforms and the single CRDs
The early phase describes the decrease in fluorescence at the temperature jump. A high affinity binding
event is seen for Gal-8S, Gal-8L and the N-terminal CRD. The late phase describes an increase in fluores-
cence at the late phase of thermophoresis. This indicates a low-affinity binding event for Gal-8L and the
C-terminal CRD. The graphs show cumulative data of three independent experiments.
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Lactose is a natural ligand for Gal-8 and used for inhibition of the lectin function.
100mM lactose was added to the MST-buffer prior to the measurement in order to
find out if a glycan ligand could interfere with di-or multimerization. Lactose was
able to inhibit all interactions and binding events were not visible anymore (Figure
3.40).
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Figure 3.40: Inhibition of di- or multimerization with lactose
The experiment was performed as described above. 100mM lactose was added to the MST-buffer, inhibiting
all binding events. The graph shows cumulative data of three independent experiments.
Mutants with partly deleted linker regions, as described above (Figure 3.23), were
additionally used for the measurements since the linker region seemed to be im-
portant for multimerization. Mut1, Mut2 and MutA showed both binding events,
whereas MutB only was able to show the low affinity binding event (Figure 3.41).
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Figure 3.41: Thermophoresis of Gal-8 mutants
The early phase describes the decrease in fluorescence at the temperature jump. A high affinity binding
event is seen for Gal-8mut1, Gal-8mut2 andGal-8mutA. The late phase describes an increase in fluorescence
at the late phase of thermophoresis. This indicates a low-affinity binding event for all mutants used. The
graphs show cumulative data of three independent experiments.
The calculated binding affinities for for all Gal-8 proteins used for thermophoresis
measurements are summarized in table 3.2.
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Protein early EC50(nM) late EC50(nM)
Gal-8S 50,619 +/-7,17 none
Gal-8L 11,816 +/-3,25 893,6 +/-281
Gal-8N 55,401 +/-13,9 none
Gal-8C none 1670,5 +/-801
Mut1 3,7258 +/-2,41 153,1 +/-28,9
Mut2 116,24 +/-5,92 521,96 +/-53
MutA 12,476 +/-3,39 297,24 +/-63,1
MutB 736,13 +/-1650
Table 3.2: Summary of calculated EC50 values
To calculate the EC50 values for the different Gal-8 proteins used in thermophoresis, curves were fit using
Hill-Equation.
The measurements indicate that the high affinity binding event is most likely due to a
dimerization of the N-terminal domain in all isoforms. The second, weaker event only
occurring in the long linker isoform might be due to the C-CRD, since this only shows
the second, weaker binding event. This differences in dimer- or multimerization might
contribute to the differences in the activity of the two isoforms.
3.6.4 Galectin-8 computational modeling
The following computer simulation was performed by Dr. Sonu Kumar (Sanford-
Burnham Medical Research Institute, San Diego).
Both isoforms of Gal-8 were computationally modeled for the linker structure. The
crystal structure for both, the N-and the C-CRD is available [112, 113], but the 3D-
structure of the linker remains unknown. Additionally, the orientation of the CRDs
to each other is not known yet. Since crystallization of the full length protein is
not possible due to the flexibility of the linker region, a computational models was
used to get information about a possible protein structure. The model shows that
the CRDs in Gal-8L seem to be more distant from each other compared to Gal-8S
(Figure 3.42). Additionally, the orientation is different in both isoforms.
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Figure 3.42: Computational model of Gal-8S and Gal-8L
The linker structures were modeled for Gal-8S (A) and Gal-8L (B) in explicit solvent for 25 ns. The model
shows that the CRDs seem to be closer to each other for Gal-8S then for Gal-8L. The experiment was
performed by Dr. Sonu Kumar (Sanford-Burnham Medical Research Institute, San Diego).
By dimerization of the N-terminal CRD of both isoforms, a further multimerization
could possibly be blocked due to sterical hindrances in Gal-8S. The linker of Gal-8S is
shorter, the space between the two CRDs seems to be fewer in Gal-8S. Additionally,
the CRDs are facing more outwards in Gal-8L, possibly displaying the binding sites
necessary for further multimerization. These calculations could possibly explain, why
the isoforms differ in their ability to built multimers in solution and why they differ
in their biological activity.
4Discussion
This thesis intended to investigate the role of Gal-8 in MM with regard to inter-
actions between MM cells and EC. I focussed on angiogenesis and homing of the
tumor cells to the BM since these are crucial steps in the progression of the disease.
It has been shown before that Gal-8 can influence angiogenesis as well as adhesion
processes, but it has never been investigated in MM and with regard to the two
different isoforms of the lectin. For Gal-9, another tandem-repeat galectin, it has
already been shown that the isoforms have different effects on angiogenesis and ad-
hesion [128, 129] indicating an impact of the linker region on the biological function
of the lectin.
In my study, I was able to show that Gal-8 has no effect on angiogenesis, since
recombinant Gal-8 was not able to enhance proliferation or the migratory potential
of EC and did not influence tube formation in an in vitro tube formation assay. But
I could reveal a pro-adhesive effect of Gal-8 in static as well as under shear stress
conditions which is higher for the Gal-8L isoform. This pro-adhesive effect could
promote the progression of the disease in vivo as Gal-8high patients have a lower
survival and a faster progression of the disease. The stronger pro-adhesive effect of
Gal-8L might be explained by multimerization of the protein which was investigated
by native SDS-PAGE, SLS analysis and thermophoresis.
4.1 Influence of Gal-8 on angiogenesis
As angiogenesis is crucial for the progression of MM and mainly induced by pro-
angiogenic factors produced by MM cells, I was wondering whether Gal-8, secreted
by MM cells, is able to promote angiogenesis in the BM. In my study, recombinant
Gal-8 neither had a positive effect on migration in a gap closure assay nor on tube
formation in a fibroblast-EC co-culture using the human primary cells HUVEC
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for the experiments. Additionally, proliferation of the cells is not enhanced by the
addition of Gal-8 to the medium.
These results are in contrast to Delgado et al. [101]. They proposed that Gal-8
induces angiogenesis which was shown by an improved network-formation using a
matrigel assay and faster migration in a wound-scratch assay in the presence of Gal-
8. These experiments were performed using bovine aortic endothelial cells (BAEC).
Additionally, they showed promotion of angiogenesis in an in vivo matrigel plug
assay in mice. Based on this publication, I wanted to validate their data using cells
of human origin since they combined bovine or mouse models with human Gal-8.
Although galectins are generally highly conserved among species, mouse, human and
bovine Gal-8 share only 70-80% sequence homology. Furthermore, the matrigel-assay
is rather a network-formation assay than a tube formation assay, since it shows only
the interconnection of plated cells. Using cell lines of human origin, I could not con-
firm a pro-angiogenic effect of Gal-8. A recent publication by Chen et al. [89] showed
that Gal-8 is enhanced in the circulation of cancer patients and stimulation of human
micro-vascular lung endothelial cells (HMVEC-L) with Gal-8 induces the secretion
of pro-angiogenic cytokines. HUVECs are, in contrast to HMVEC-L, derived from
the macrovasculature. Maybe the pro-angiogenic effect depends on the EC subtype
or in general on the model system used for the experiments. Further research has to
be performed in order to investigate the function of Gal-8 in angiogenesis.
4.2 Influence of Gal-8 on MM homing
Previous studies described that Gal-8 influences cell-cell interactions in general [75,
76, 77, 78]. But it has not been assessed whether it also influences the adhesion of MM
cells to EC, which is a crucial step in the progression of MM. I was able to show that
Gal-8 enhances the adhesion of MM cells to HUVEC in a static environment. Gal-8L
had a stronger pro-adhesive effect than Gal-8S. This is the first study showing that
the Gal-8 isoforms differ in their biological activity. The N-terminal domain alone
had no such effect, indicating that either both domains or the C-CRD is important
for the adhesion.
Since whole genome microarray analyses revealed that the expression of adhesion
molecules changes remarkably after shear stress or during inflammatory stimulation
using TNF-α, interaction studies between MM and ECs were also performed under
shear stress conditions. Even under flow, recombinant as well as MM cell derived
Gal-8 was able to significantly promote adhesion indicating that Gal-8 could be an
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important factor in MM homing in the absence of an inflammatory environment.
As Gal-8 is a galectin consisting of two CRD connected by a linker region, one idea
explaining this pro-adhesive effect was that one CRD could possibly bind MM cells
while the other prefers EC and connects thereby the two cells. As the N-terminal
domain prefers sialylated structures for binding and the C-terminal domain binds
non-sialylated glycans such as blood-group A and B antigens, the sialylation status
of MM and EC was investigated by MAA and SNA binding in order to find out
whether one cell type possibly prefers binding of one of the CRDs. MM as well as
EC have both, α2,3 and α2,6 sialylated structures on their cell surface. But Gal-
8N binding after VCN treatment was only affected on EC as seen by a reduction
of the MFI after desialylation. The binding on MM cells was not reduced after
neuraminidase-treatment and on MOLP-8, both isoforms of the full-length protein
even displayed increased binding after VCN-treatment. For LP-1, binding of both
full-length isoforms was decreased after desialylation, as in EC. These experiments
indicate that the C-CRD might favor MM cells, whereas the N-CRD prefers EC. Of
course, the VCN treatment only gives a rough estimate. Binding specificities of both
CRDs on the respective cellular partner certainly also depend on other conditions, as
for example the arrangement of glycoconjugates on the cell surface (microdomains)
or the length of a receptor candidate. This fact might explain, why the MM cells
lines MOLP-8 and LP-1 differ in binding of Gal-8 after VCN treatment.
Still, ligands for the binding of Gal-8 to the surface of MM and EC have to be
identified. One possible group of candidates for this type of interaction are inte-
grins, which are expressed on both cell types and have been reported before to bind
Gal-8 [77, 130]. Integrins are known to play key roles in the firm adhesion of leu-
cocytes to EC during the rolling/adhesion cascade. Gal-8 could possibly strengthen
the leucocyte-EC interactions as a co-factor for firm adhesion. Also, other glycosy-
lated targets are possible and Gal-8 might play a role very early in homing com-
parable to selectins promoting the first rolling events during the adhesion cascade.
But in general not much is known about Gal-8 binding partners and identification
of those is difficult since there are many possible targets. Galectins can either bind
carbohydrate-specific via their CRDs or use protein-protein interactions for binding.
For MM and EC, binding seems to be carbohydrate-dependent, since the binding
was inhibited by the addition of lactose.
4.3 Differences in biological activity of the isoforms
In this work, different than in other studies, both Gal-8 isoforms were used for the
in vitro experiments. Most research done on Gal-8 claims that the isoforms do not
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differ in their biological activity using only the short-linker isoform for experiments.
In our group we were able to show on the one hand that Gal-8L has stronger pro-
adhesive effects on MM adhesion to EC (my study) and on the other hand that only
Gal-8L, but not Gal-8S is able to induce apoptosis in the pre-B cell line NALM-6
(Master thesis of Michal Stanczak). These results lead to the question, why these
differences in biological activity of Gal-8 isoforms occur and what the mechanism
behind this phenomenons are. For the pro-apoptotic effect of Gal-8L and the N-
terminal CRD, a protease cleavage site present in the long-linker but not in the short-
linker isoform could possibly explain the difference in biological activity. Proteolytic
cleavage of Gal-8L results in single CRDs but with a shorter linker part. Both, the
single recombinant N-CRD without a linker and the proteolytically cleaved N-CRD
with a shortened linker part could induce apoptosis in NALM-6. Therefore, the N-
CRD may be the driving force for induction of apoptosis and the C-CRD may be, at
least for this biological function, not essential. In contrast, the difference in homing
can not be explained by proteolytic cleavage of Gal-8L, since both domains seemed
to be necessary for the pro-adhesive effect.
As galectins have been described to be able to form complex glycan-galectin
lattices, the question arises whether multimerization processes or lattice formation
influence cell-cell adhesion. Using non-reducing SDS-PAGE, I was able to show that
Gal-8 can exists as di- or multimers, depending on the isoform, without the need of
chemical crosslinking. Gal-8L was present as a trimer, whereas for Gal-8S only dimers
were visible in the gel. These findings were confirmed by SLS analysis and indicate
that Gal-8L more readily builds dimers in solution and has a stronger capability of
self-interaction. The calculated size for monomers as well as dimers in SLS analysis
differed from a theoretical size of the proteins. This could point to the possibility
that Gal-8S and Gal-8L differ in their conformation.
MST analysis revealed that Gal-8L, in contrast to Gal-8S, shows two different
binding events. The first high affinity binding might be due to a interaction of two
N-terminal CRDs and is also present in Gal-8S. The second, weaker binding event
is possibly a non-covalent interaction of two C-CRDs which is not seen for Gal-
8S. Due to sterical hindrances caused by the shorter linker and less flexibility, a
second binding event might not be possible for Gal-8S, but for Gal-8L. After the
addition of lactose to the MST-buffer in order to mimic binding of a natural ligand
during di- or multimerization in solution, no self-interaction was measured anymore,
indicating that self-interaction of Gal-8 is independent of a ligand in solution and
even interrupted when a ligand is present. Carbohydrate binding could lead to a
conformational change in the CRD masking the regions important for dimerization
of the single CRDs. As Gal-8 is present in serum, the question arises whether it
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exists as di- or multimers or if carbohydrates present in the serum prevent the self-
interaction of Gal-8 in vivo. It has to be noticed, that the dimerization of Gal-8
occurs with very high affinity with a EC50 of 12nM for Gal-8L and 50nM for Gal-8S.
The highest serum Gal-8 concentration measured in MM patients was 37pM which
is approximately 1000-fold less than necessary for self-aggregation. So it is unlikely
that Gal-8 is present as di- or multimers in the serum. Still, local concentrations
of the protein could be in nano-molar ranges allowing for dimerization. In this case
the aggregated Gal-8 may prevent “unwanted” interactions with glycoproteins in
the blood stream, as dimerization could block the binding of certain ligands. At
the cell surface, aggregated Gal-8L may help to bring distinct binding partners into
proximity and thereby facilitate adhesion processes.
Since crystallization of the full-length protein has not been performed yet, no data
about the structure of the complete protein is available. There are only crystal-
structures of the single N- or C-CRDs available and a mutant without a linker
between the CRDs. Computational modeling using the crystal structure of the single
CRDs connected by the insertion of the linker amino acid sequence for both isoforms
was performed by Sonu Kumar in order to obtain more insights into the possible
structure of the entire protein and whether the conformation of the linker influences
the positions of the CRDs to each other. The model suggests that the linker is rather
twisted and not stretched forming a loop bringing the CRDs in close proximity to
each other. The carbohydrate binding grooves face outwards away from each other.
For Gal-8S, the CRDs seem to be closer to each other than for Gal-8L possibly
causing a steric hindrance for further multimerization after the formation of a Gal-
8S dimer. For Gal-8L, the CRDs are further away from each other, enabling a second
binding event. Additionally, as the linker in Gal-8S is shorter, the long linker isoform
might be more flexible in stretching of the linker region after dimerization of one of
the CRDs allowing further multimerization.
In 2007, Rabinovich et al. [58] predicted a model for galectin-multimerization and
proposed a theory for the formation of galectin-glycan lattices on the cell surface.
The model is shown in the introduction Figure 1.8 and Figure 4.1. Although it is
frequently used, several papers question this model. Lepur et al. [131] were able to
show in 2012 that Gal-3 seems not to be a pentamer in solution if a ligand is present
and rather multimerizes via the CRDs and not by binding the amino-acid tail. The
Gal-8 N-CRD has been shown to run as a dimer in a SDS-PAGE after chemical
crosslinking without a ligand present [98], two Gal-1 CRDs connected by artificial
linkers have been shown to homodi - and multimerize [60]. These findings indicate,
that galectin-glycan lattice formation and multimerization is a much more complex
process than it has been assumed up to now. Additionally, it has to be mentioned
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that di- or multimerization is a mechanism that must not be connected to lattice
formation. Both processes can occur in absence or presence of a ligand and have to
be investigated separately. Even though some galectins are able to di- or multimerize
it does not necessarily implicit lattice formation on the cell surface.
Taken together all results of my and published interaction-studies, I conclude
that Gal-8S and Gal-8L differ in their ability of self-interaction. This self-interaction
is independent of a ligand and occurs in solution. The lattice-formation model of
Rabinovich et al. [58] has to be extended. From my finding, I propose that the
tandem-repeat Gal-8 is able to form dimers or even multimers, depending on the
isoform. Binding of a ligand leads to the abrogation of the self-interaction (Figure
4.1).
lattice formation
Ligand
Galectin-8S Galectin-8L
Dimer
Trimer
Tetramer
Ligand-dependent model Ligand-independent model 
Figure 4.1: Model for ligand-independent di- or multimerization of Gal-8
The ligand-dependent lattice formation model was proposed by Rabinovich et al. [58] in 2007. It describes
the interaction of tandem-repeat galectins with ligands on the cell surface crosslinking cell surface receptors.
There is no experimental evidence that this process occurs in vivo and in vitro. I propose a ligand indepen-
dent di- or multimerization for the tandem-repeat Gal-8, depending on the isoform. This self interaction
is abrogated if a ligand is present in the solution.
The difference in their ability of self-interaction could also explain differences
in the biological activity of both isoforms in terms of homing. The activity of the
lectin could be influenced by the di- or multimerization of the protein. As Gal-8L is
able to form higher-ordered aggregates, more proteins can bind to the cell surface
in closer proximity to each other without sterical hindrances as compared to Gal-
8S. This could result in better pro-adhesive capacities of Gal-8L by binding more
carbohydrate ligands on MM and EC surfaces as shown in Figure 4.2.
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Endothelial cell
MM cell
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Figure 4.2: Homing of MM to EC
Possible influence of Gal-8 di- or multimerization on adhesion of MM to EC.
4.4 Gal-8 in MM disease progression
MM is a very heterogenous disease in terms of gene expression, hence it is difficult to
identify and define prognostic markers or new treatment targets. Today, still many
patients have a relapse due to treatment-resistant MM clones and a cure of the
disease is not possible at the moment. Identifying novel drug-targets may improve
clinical outcomes, new prognostic markers could help for the selection of treatment
options according to a patients’ risk type and give the opportunity of individualized
therapy.
My studies showed that Gal-8 serum levels were higher in many, but not all,
MM patients compared to HD and further survival analysis revealed that patients
expressing high Gal-8 mRNA levels have a shorter survival and a faster progres-
sion compared to patients with low Gal-8 expression. This negative effect of Gal-8
transcription is also reflected by the correlation of high Gal-8 expression with chro-
mosomal aberrations that are known to occur frequently in MM. The gal-8 gene
is located on chromosome 1 (1q43), one frequent aberration correlating with Gal-
8 expression is the gain of 1q21. As the positions 1q21 and 1q43 are close to each
other, duplication of 1q21 could possibly also regulate the expression of Gal-8 leading
to higher transcription of the gene. The analysis of MM patients’ samples indicated
that Gal-8 influences MM progression. According to my observations, Gal-8 could be
used as an additional prognostic marker for MM since the disease seems to progress
more aggressively in individuals with high Gal-8 expression.
It is noticeable that the mean Gal-8 concentration in the serum of HD as well as
in MM patients was much lower as compared to other studies that measured Gal-8
serum levels in colon and breast cancer patients [74]. In those studies the Gal-8
concentration was determined to be an average of 10ng/ml ranging from approxi-
mately 0.1 to 100ng/ml. These differences to my study may be due to the specificity
of the Gal-8 ELISA. Barrow et al. [74] used a polyclonal catcher antibody and the
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same antibody coupled to biotin for detection. Performing an ELISA with two poly-
clonal antibodies may cause unspecific binding as well as detection of other serum
galectins, since they are very homologous. In my study, I applied a monoclonal an-
tibody as catcher antibody and the biotinylated polyclonal antibody for detection.
Using a monoclonal catcher antibody leads to a higher specificity of the ELISA and
therefore more reliable data with regard to Gal-8 serum concentrations.
Observing the pro-adhesive effect of Gal-8 a question that arises is: where does
Gal-8 actually come from in vivo? Both, MM cells as well as EC are able to produce
and secrete Gal-8. Therefore, the protein in the serum could come from both or
from other sources. But due to experimental constraints, the isoforms present in
the serum could not be defined. Intracellularly, MOLP-8 produces less Gal-8L than
Gal-8S, EC produce both isoforms in comparable amounts. The question is whether
MOLP-8 is able to selectively secrete Gal-8L into the supernatant because of its
stronger pro-adhesive properties. Nevertheless, even if only Gal-8S is secreted and
present in the serum, this also has an pro-adhesive effect though with lower affinities.
For further experiments an isoform-specific ELISA should be developed in order to
define the ratios of Gal-8S to Gal-8L in the sera and supernatants used for adhesion
assays.
To solve the question where Gal-8 originates from, further in vivo studies have
to be performed. Histopathology of BM sections could show if Gal-8 is present in
the BM microenvironment and which cells could be the main producers.
In which stage of the disease is a pro-adhesive effect of Gal-8 in a non-inflammatory
environment beneficial? Usually, an inflammatory environment is crucial for the ad-
hesion of leucocytes, since most adhesion molecules are only expressed in inflamed
tissues. Gal-8 promotes adhesion even without prior stimulation of the EC. Since
the whole genome array covers both isoforms for expression analysis, the effect of
the isoforms could not be taken into account. Nevertheless in view of Gal-8high pa-
tients’ lower survival rate and faster progression of the disease, Gal-8 could either
promote the first homing steps of MM cells to the BM or allow the circulating MM
cells to home into different sites of the disease without the dependance on other
adhesion molecules. Still, it must be noticed that Gal-8 also has a beneficial, though
small effect on adhesion in an inflammatory environment. During the progression
of the disease, many pro-inflammatory cytokines are produced by MM cells leading
to an inflammatory situation in the BM microenvironment [1]. Gal-8 has also been
shown to further increase the adhesion of MM cells to EC, which is already strong
after TNF-α stimulation due to the expression of many other adhesion molecules
like E-selectin or ICAM-I. So even in later stages of the disease, Gal-8 expression
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and secretion can be beneficial for MM cells in terms of homing and spreading of
the disease.
Comparing the experimental set-up with the in vivo situation, one recognizes
that the serum level in MM patients had a maximum at 1.33ng/ml (37pM), the
mean concentration was 0.22ng/ml (6pM). This is around 5000-fold lower than the
concentration used for in vitro adhesion assays which was 100nM. It has to be con-
sidered that serum was used for the analysis and not fresh plasma or whole-blood
samples. Some Gal-8 might be lost during the coagulation of blood proteins since
galectins are rather sticky proteins with a tendency for aggregation. Additionally, the
local concentrations e.g. in the bone marrow might be higher in sites of MM adhe-
sion. Furthermore, Gal-8 conditioned medium with mean concentration of 0.33ng/ml
(9pM) Gal-8 was able to enhance adhesion compared to Gal-8 depleted medium in-
dicating that lower Gal-8 concentrations might still be effective. SDS gels stained
with Comassie brilliant blue showed some degradation products in the recombinant
protein. So may be lower concentrations of active protein were actually used in this
study.
4.5 Gal-8 as target for anti-myeloma therapy
Targeting homing mechanisms in MM treatment seems to be beneficial and preven-
tion of MM-EC interactions could disrupt the disease spreading in the BM. Further-
more, more cells could be forced to circulate in the blood stream by the inhibition
of MM-EC interactions leading to an improved susceptibility for other drugs.
Since it has been described that galectins might play a role in cancer and other
diseases, anti-galectin compounds may be used for treatment. For this purpose,
several modes of galectin-intervention could be tried, for example natural ligands,
carbohydrate analogues of natural ligands or anti-galectin antibodies [132]. For Gal-1
and Gal-3, several trials have been made using different galectin antagonists. DB21,
an allosteric antagonist of Gal-1 was used to inhibit tumor angiogenesis and tumor
growth in mouse models [133], in a breast cancer model Gal-1 blocking disaccharides
were successfully administered as an adjuvant therapy promoting immune responses
[134]. Two studies using the Gal-3 inhibitors GR-MD-01 and GR-MD-02 reveal their
function in treatment of liver fibrosis and steatohepatitis in mice [135, 136]. In MM
GCS-100, a Gal-3 antagonist, was shown to inhibit tumor cell growth in vitro [82].
But no clinical studies in humans proofing the effectiveness of these drugs in patients
have been published yet.
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These studies show in principle, that galectin-antagonists are a therapeutic option
that should be considered in diseases where galectins are involved. Up to now, no
Gal-8 specific inhibitor has been developed which may be an option for treatment of
Gal-8high MM patients. But still more experiments have to be performed, in order to
find out which role Gal-8 plays in MM and how it influences the progression of the
disease. Pro-adhesive effects of Gal-8 have not only been shown concerning MM-EC
interactions, PBMC from healthy donors are also able to adhere stronger to HUVEC
in the presence of Gal-8 [137]. Blocking these interactions could interfere with basic
functions of the immune system, more experiments need to be performed in order
to investigate the role of Gal-8 in healthy individuals.
In conclusion, I was able to show that Gal-8 influences MM biology by enhancing
the binding of MM cells to EC and thereby possibly influencing the progression of
the disease and the survival time of the patients. Additionally, this study shows
for the first time that the two isoforms of Gal-8 have different activities in vitro.
These differences must be considered in further studies by taking both isoforms into
account.
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